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Preface: 
 
Clozapine is a drug of choice for treatment of refractory schizophrenia, which is 
primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main 
metabolite. There are reports of wide ranging gastrointestinal side effects associated with 
clozapine therapy, that result in concomitant administration of proton pump 
inhibitors to treat acid-related disorders. Omeprazole is an established CYP1A2 
inducer, while an in vitro study has shown that rabeprazole is much less potent in 
this regard. There is no available information about the impact of rabeprazole on 
CYP1A2 activity in patients.  
 
Firstly, this information is essential when prescriptions are changed from 
omeprazole to rabeprazole to reduce medication costs. Therefore, the aim of this 
study was to compare the effects of rabeprazole and omeprazole on CYP1A2-
mediated clearance (CL/F) of clozapine. 
 
Secondly, the effective dosage of clozapine varies widely among patients, making it 
necessary to individualize drug therapy with clozapine. The reason for dosage variation 
could be due to the influence of patient-related variables on clozapine plasma 
concentrations. Therefore, another aim of this study was to investigate the relationship 
between patient variables, such as age, gender, cigarette smoke, weight and body mass 
index and clozapine clearance (CL/F). 
 
 iv
A cross-over study design was used for this study. Twenty patients from Macquarie 
hospital who were receiving clozapine and rabeprazole (with no other interacting 
medications) were recruited in this study. Blood samples were taken at 30 min, 1 hr, 
2 hr and 12 hr after a dose of clozapine. Rabeprazole was then replaced with  
omeprazole. After at least 1 month blood samples were again collected at the above 
corresponding intervals after clozapine. The plasma concentrations of clozapine and 
norclozapine were determined by high performance liquid chromatography. Abbottbase 
Pharmacokinetic Systems Software, which utilizes Bayesian forecasting, was used to 
estimate pharmacokinetic parameters of clozapine. The ratio of plasma 
norclozapine/clozapine concentrations at trough level was used to reflect CYP1A2 
activity. 
 
No difference was observed in clozapine clearance (CL/F) and CYP1A2 activity 
during concurrent therapy with either rabeprazole or omeprazole. 
According to some studies CYP1A2 induction by omeprazole is dose dependent. 
Furthermore, since rabeprazole is a weak CYP1A2 inducer in vitro, we conclude 
that omeprazole and rabeprazole may not induce CYP1A2 activity when used at 
conventional therapeutic dosage (<40 mg/day). Hence, replacement of omeprazole 
with rabeprazole at conventional therapeutic dosages (20 or 40 mg daily) offers no 
advantages in the management of patients with schizophrenia on clozapine and no 
dose adjustment is required.  
 
 v
Consistent with previous studies, clozapine concentrations were found to be 
significantly lower in cigarette smokers due to CYP1A2 induction.  
No relationship was found between age, gender, or weight and clozapine clearance 
(CL/F). However, body mass index showed a significant negative correlation with 
clozapine clearance (CL/F).  
Since weight gain and lipid accumulation are common side effects of clozapine they 
may be associated with a reduction of CYP1A2 activity and clozapine clearance 
(CL/F). Moreover, high lipoprotein levels may decrease the unbound fraction of 
clozapine and decrease the availability of clozapine for oxidation by cytochrome 
P450 enzymes.   
 
Therefore, it is concluded that omeprazole and rabeprazole may not induce CYP1A2 
activity when used at conventional therapeutic dosage (<40mg/day). Hence, 
replacement of omeprazole with rabeprazole does not require the dose of clozapine 
to be adjusted. Moreover, the negative correlation between clozapine clearance 
(CL/F) and BMI is informative. Further studies are now required to clarify the 
relationship between BMI, lipoprotein levels and clozapine clearance in patients 
with schizophrenia. 
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CHPTER ONE: 
LITERATURE REVIEW 
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1.1. Cytochrome P450 and the Clearance of Xenobiotics 
 
We are continually exposed to foreign chemicals from a number of different sources. 
The different sources of xenobiotics include the diet, food additives, cosmetic 
products and environmental pollutants. In addition, drugs are another important 
source of xenobiotics. Generally, xenobiotics are lipophilic chemicals, which are 
metabolized by complex enzymatic pathways in order to be cleared from the body. 
Cytochrome P450 enzymes (CYPs) are a major group of heme-containing microsomal 
enzymes involved in the metabolism of drugs. This enzymatic pathway is also 
responsible for the biosynthesis and degradation of endogenous compounds such as 
steroids, lipids, and vitamins (Gonzalez & Tukey 2004; Wilkinson 2005). 
 
 
1.1.1. Drug Metabolism 
 
Many drugs are hydrophobic which allows them to enter cells through lipid bilayers 
so that they may interact with intra-cellular receptors and other targets. This 
hydrophobic feature of drugs makes them difficult to be eliminated from the body. 
With a few exceptions, most drugs undergo phase 1 and phase 2 metabolism by 
different isoenzymes of CYP to increase their water solubility and promote their 
elimination in urine or bile.  
In phase 1, drugs undergo oxidation, reduction or hydrolytic reactions. These 
chemical reactions occur mainly through the action of CYPs. During phase 1 some 
functional groups such as –OH, -COOH, and -O- are added to substrate in order to 
increase water solubility and which usually results in an inactive metabolite. However 
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in some cases, inactive drugs (pro drugs) are converted to active drugs by phase 1 
metabolism. 
Phase 1 is followed by phase 2 metabolism in which further enzymes form polar 
conjugates of the phase 1 metabolites. Phase 2 includes glucuronidation, sulfation, 
accetylation, or methylation and increases the elimination of drug from tissues 
(Gonzalez & Tukey 2004). 
 
 
1.1.2. Overview of the CYP System 
 
CYPs are a group of hemoproteins composed of a constant coenzyme (iron-
protoporphyrin IX) and a variable protein (Figure 1.1). The substrate specificity of 
different CYPs is due to these differences in the protein portion (Testa & Kramer 
2007).  Beside liver, which is the major site of CYP expression, the epithelium of the 
small intestine, lungs, brain and skin are other important sites of expression 
(Wilkinson 2005). 
 
The CYPs are membrane-bound enzymes. They are embedded in the lipid bilayer of 
the smooth endoplasmic reticulum membrane, although steroid metabolizing CYPs 
are located in mitochondria (Tanaka 1998; Testa & Kramer 2007). CYPs are 
connected to the membrane bilayer by their N-terminal region and to the cytosol via 
their C-termini (Testa & Kramer 2007). CYPs interact with flavoprotein NADPH and 
NADH cytochrome P450 oxidoreductases which transfer electrons to the CYPs. 
Figure 1.2 illustrates the interactions between CYPs and NADPH-CYP reductase 
within the membrane. 
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Figure 1.1. The overall fold of CYP1A2 (Lozano et al 1997) 
 
 
 
 
Figure 1.2. The membrane location of CYP (Testa & Kramer 2007) 
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The main function of the CYP system is monooxygenation. Iron-protopophyrin IX 
binds O2 in the CYP active site. CYP accepts O2 and an electron from NADPH, 
reduces and cleaves molecular oxygen, which allows one O-atom to be transferred to 
the substrate (Testa & Kramer 2007). Among the reactions carried out by CYPs are 
N-dealkylation, O-dealkylation, aromatic hydroxylation, N-Oxidation, S-oxidation, 
deamination, and dehalogenation as shown below, where X = substrate and XO = 
oxidized metabolite  
 (Gonzalez & Tukey 2004).  
 
 
 
 
 
CYPs are classified by their amino acid similarity. Cytochromes with 40% or greater 
sequence homology are placed in the same family, and those with 55% or greater 
homology are placed in the same subfamily (Nelson et al 1996). For instance, based 
on this nomenclature, CYP2C19 belongs to the subfamily C within family 2.   
 
 
 
 
 
 
 
 
The nomenclature of CYP genes 
    
  CYP (root) 
 
          2 (family) 
  
                C (sub-family) 
 
                      19 (individual gene)    
XH + O2 + 2 e- + 2 H+  Æ  XOH + H2O 
 
Or 
 
X + O2 + 2 e- + 2 H+  Æ  XO + H2O 
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To the present, 57 CYP genes have been identified in humans. Only a few of them are 
associated with the metabolism of drugs, mainly in the CYP1, CYP2 and CYP3 
families (Wilkinson 2005). It has been estimated that six enzymes, CYP1A2, 2C9, 
2C19, 2D6, 2E1 and 3A4/5, are responsible for oxidation of 90% of human drugs 
(Tanaka 1998).   Individual CYP forms show affinity toward structurally unrelated 
compounds. Thus, more than one CYP may contribute to the metabolism of a 
particular drug (Gonzalez 1988). This unusual overlap of CYP activities is one of the 
main reasons for drug-drug interactions. Furthermore, the activity of CYPs may vary 
because of individual differences in expression (Roots et al 2004). Mutations in CYP 
genes can also contribute to inter or intra-individual differences in metabolism 
(Nebert & Russell 2002).  
 
 
CYP1 family: 
The members of this family include CYP1A1 and CYP1A2. CYP1A1 is located 
mainly in extrahepatic tissue, while CYP1A2 is expressed in liver and accounts for 
about 15% of the total hepatic CYP content (Raunio et al 1995). The CYP1 family is 
mainly responsible for the metabolism of planar polyaromatic/heterocyclic amines 
and amides, polycyclic aromatic hydrocarbon (PAHs), and polyhalogenated aromatic 
hydrocarbons (PHAHs). PAHs and PHAHs are potent inducers of the CYP1 family 
due to their strong affinities for the aryl hydrocarbon receptor (AHR), which is a 
member of the helix-loop-helix group of transcription factors (Nebert & Dalton 2006). 
CYP1A2 also metabolizes about 24 drugs, while CYP1A1 and CYP1B1 are less 
involved in drug metabolism (Nebert & Dalton 2006). Caffeine, a drug which is 
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highly dependent on CYP1A2 for its metabolism, can be used as a specific probe for 
in vivo CYP1A2 phenotyping. Thus, the paraxanthine/caffeine concentration ratio in 
plasma or urine reflects CYP1A2 activity (Doude van Troostwijik et al 2003b). Some 
commonly used drugs have been shown to induce and inhibit CYP1A2 activity. For 
example fluvoxamine is associated with CYP1A2 inhibition (Rasmussen et al 1995). 
Table 1.1 shows the main substrates, inducers and inhibitors of CYP1A2.  
Some single nucleotide polymorphisms (SNPs) of the CYP1A2 gene have been 
identified in the 5 - flanking region and in intron 1 of CYP1A2 
(www.imm.ki.se/CYPalleles/cyp1a2.htm). Some of these are associated with the 
inducibility of CYP1A2 expression in smokers. For example, a study of 185 healthy 
Caucasian non-smokers and 51 smokers identified a -164CÆA SNP in intron 1 of the 
CYP1A2 gene (the CYP1A2*1F allele). In this study, smokers with the A/A genotype 
showed a 60 % to 70% higher CYP1A2 activity than those with either A/C or C/C 
genotype. It appears that the CYP1A2*1F allele which is observed in one-third of 
Caucasians could represent a highly inducible genotype of CYP1A2 (Sachse et al 
1999). Another SNP identified in CYP1A2 is the -360 CÆA polymorphism 
(CYP1A2*1C allele), which shows a lower activity in smokers and non-smokers (Han 
et al 2001). Despite these recent findings, Catteau et al have suggested that genetic 
factors are probably negligible in overall CYP1A2 activity (Catteau et al 1995). This 
is compatible with the very low incidence of SNPs in the coding region of CYP1A2 
that produce altered polypeptide sequences. 
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Table 1.1. Some Important Substrates, Inhibitors and Inducers of CYP1A2 
(www.medicine.iupui.edu/flockhart/table.htm; 27/10/2006) 
 
CYP1A2 substrates CYP1A2 inhibitors CYP1A2 inducers 
      
Antidepressants Amiodarone Smoking 
Amitriptyline Cimetidine Omeprazole 
Clomipramine Ciprofloxacine Rifampicin 
Imipramine Fluoroquinolones Barbiturates 
Fluvoxamine Fluvoxamine Phenytoin 
Antipsychotics Interferon Carbamazepine 
Haloperidol Methoxsalen Insulin 
Clozapine Mibefradil  
Olanzapine   
Methylxanthine/s   
Theophylline   
Caffeine   
Others   
Paracetamol   
Phenacetin   
Tacrine   
   
 
 
 
 
CYP2C subfamily: 
It has been suggested that the CYP2Cs have the most complex drug metabolizing 
properties of any subfamily (Rettie et al 2000). The CYP2C subfamily includes 
CYP2C8, CYP2C9, CYP2C18 and CYP2C19 and accounts for about 20% of total 
hepatic CYPs (Rettie et al 2000). The CYP2C subfamily is also associated with 
extensive pharmacogenetic variation. For example, 2% to 5% of Caucasians and 13% 
to 23% of Asians are poor metabolizers (PMs) for CYP2C19, and the remainders are 
extensive metabolizers (EMs) (Rettie et al 2000).  Approximately 95% of the 
population exhibits two particular variant alleles of CYP2C19 (CYP2C19*2 and 
CYP2C19*3) that have been shown to result in the PM phenotype (Wedlund 
2000). Diazepam is predominantly metabolized by CYP2C19. Thus, the plasma 
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concentrations of diazepam are higher in PM, which may result in prolongation 
of sedation in individuals exhibiting this phenotype (Rettie et al 2000). Proton 
pump inhibitors (PPIs) are also major substrates for CYP2C19. Studies have 
shown that the rate of healing for both gastric and duodenal ulcers with PPI 
therapy can be affected by CYP2C19 genotype and is more rapid in PMs (Furuta 
et al 1998; Klotz 2006). Hydroxylation of S-mephenytoin and omeprazole, which 
are prototype reactions for this enzyme, may be used for the determination of 
CYP2C19 activity (Testa & Kramer 2007). Table 1.2 shows major substrates, 
inducers and inhibitors of CYP2C19.  
 
Genetic polymorphism is also exhibited by CYP2C9, the most abundant member 
of the CYP2C subfamily (Rettie et al 2000). A comprehensive review by Daly 
and King suggests that the maintenance dose of warfarin, which is primarily 
metabolized by CYP2C9, is dependent on CYP2C9 genotype (Daly & King 
2003).   For instance, patients who are heterozygous for CYP2C9*2/*3 may require 
lower doses than those who are homozygous or heterozygous for the wild-type 
enzyme (Daly & King 2003). Hydroxylation of diclofenac and tolbutamide are further 
reactions that can be attributed to CYP2C9 (Testa & Kramer 2007). Table 1.3 shows 
the principal substrates, inducers and inhibitors of CYP2C9. The available evidence 
suggests that the clinical importance of CYP2C8 and CYP2C18 is lower than 
other CYPs 2C.  
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Table 1.2. Some Important Substrates, Inhibitors and Inducers of CYP2C19 
(www.medicine.iupui.edu/flockhart/table.htm; 27/10/2006) 
 
 
CYP2C19 substrates 
 
CYP2C19 inhibitors 
 
CYP2C19 inducers 
 
Proton Pump Inhibitors Chloramphenicol Carbamazepine 
omeprazole Cimetidine Prednisone 
Lansoprazole Fluoxetine Rifampicin 
Pantoprazole Fluvoxamine  
Rabeprazole Indomethacin  
Anticonvulsants Ketoconazole  
Diazepam Lansoprazole  
Phenytoin Omeprazole  
Primidone Probenecid  
Phenobarbitone Ticlopidine  
Antidepressants Topiramate  
Amitriptyline   
Clomipramine   
Imipramine   
Moclobemide   
Others   
Citalopram   
Indomethacin   
Propranolol   
Cyclophosphamide 
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Table 1.3. Some Important Substrates, Inhibitors and Inducers of CYP2C9 
(www.medicine.iupui.edu/flockhart/table.htm; 27/10/2006) 
 
 
CYP2C9 substrates 
 
CYP2C9 inhibitors 
 
CYP2C9 inducers 
 
NSAIDs Amiodarone Rifampin 
Diclofenac Fluconazole Secobarbital 
Ibuprofen Fluvastatin  
Meloxicam Fluvoxamine  
S-naproxen Isoniazid  
Piroxicam Lovastatin  
Oral Hypoglycemic Agents Sertraline  
Tolbutamide Zafirlukast  
Glyburide   
Glibenclamide   
Glipizide   
Angiotensin II Antagonists   
Losartan   
Irbesartan   
Others   
Amitriptyline   
Fluoxetine   
Phenytoin   
Tamoxifen   
Torsemide   
S-warfarin     
 
 
 
 
CYP2D subfamily: 
The CYP2D gene is located on human chromosome 22 and is a CYP that has clinical 
importance in the metabolism of xenobiotics (Heim & Meyer 1992). The CYP2D6 
enzyme is responsible for the metabolism of 25% of known drugs, and among them 
antipsychotic and antidepressant agents are major substrates (de Leon et al 2006). 
Table 1.4 shows some important substrates, and inhibitors of CYP2D6; although 
certain studies have suggested that CYP2D6 is inducible, the majority of studies do 
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not suggest this. CYP2D6 is highly polymorphic and more than 80 different alleles 
have been recognized (Heim & Meyer 1992). CYP2D6 expresses four different 
phenotypes in man. The ultra-rapid metabolizers (UMs) have three or more copies of 
active alleles. 1% to 10% of Caucasians and up to 2% of Asians are UMs. The 
extensive metabolizers (EMs) are normal subjects. This group has two active alleles; 
although there are a number of possible active alleles. Intermediate metabolizers 
(IMs) have one nonfunctional allele so that CYP2D6 activity is lower than in EMs. 
The poor metabolizers (PMs) do not have functional alleles. 5% to 10% of Caucasians 
and 1% of Asians are PMs (de Leon et al 2006). The PM phenotype is clinically 
important because of the likelihood of adverse reactions caused by increased plasma 
concentrations. In addition, lack of drug efficacy may be observed in UM subjects 
because of their capacity to clear CYP2D6 substrates (Wilkinson 2005). The 
antidepressant desipramine is metabolized by CYP2D6. It is recommended that 
patients with the PM phenotype should take 30% of the standard dose and UMs need 
a higher than average dose of desipramine (Thuerauf & Lunkenheimer 2006). This 
study suggests that, because CYP2D6 is the predominant pathway for the metabolism 
of antidepressants, and CYP2D6 is highly polymorphic, routine phenotyping in 
psychiatry could be helpful in directing the dosage of antidepressants. Hydroxylation 
of debrisoquine and demethylation of dextromethorphan are two drug oxidations that 
are diagnostic for CYP2D6 activity (Testa & Kramer 2007). 
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Table 1.4. Some Important Substrates, and Inhibitors of CYP2D6 (Wilkinson 2005) 
 
CYP2D6 Substrates CYP2D6 Inhibitors 
    
Beta Blockers Tricyclic Antidepressant 
Alprenolol Clomipramine 
Bufuralol  
Carvedilol Antiarrhythmic agents 
S-metoprolol Quinidine 
Propranolol  
Timolol Antipsychotic agents and SSRIs 
Tricyclic Antidepressant Fluoxetine 
Amitriptyline  Haloperidol 
Clomipramine Paroxetine 
Imipramine  
Nortriptyline  
Antiarrhythmic agents  
Flecainide  
Mexilletine  
Antipsychotic agents and 
SSRIs  
Fluoxetine  
Haloperidol  
Paroxetine  
Perphenazine  
Venlafaxine  
Opioids  
Codeine  
Dextromethorphan  
 
 
 
 
CYP3A subfamily: 
The CYP3As are responsible for the disposition of more than half of the known drugs. 
Table 1.5 shows some important substrates, inhibitors and inducers of CYP3A4. This 
enzyme is primarily expressed in the liver and the intestinal epithelium (Wilkinson 
2005). The two principal enzymes of this subfamily - CYP3A4 and CYP3A5 - have 
very similar substrates specificities which makes it difficult to distinguish them. The 
activities of other CYP3A enzymes, such as CYP3A43, are very low compared to the 
other CYP3As, and CYP3A7 is primarily a fetal enzyme (Wilkinson 2005).  
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Table 1.5. Some Important Substrates, Inhibitors and Inducers of CYP3A (Wilkinson 2005) 
 
CYP3A Substrate CYP3A Inhibitors CYP3A Inducers 
      
Calcium Channel Blockers Calcium Channel Blockers Rifamycins 
Dilitiazem Diltiazem Rifabutin 
Felodipine Verapamil Rifampin 
Nifedipine Azole Antifungal agents Rifapentine 
Verapamil Itraconazole Anticonvulsant agents
Immunosuppressant agents Ketoconazole Carbamazepine 
Cyclosporine Macrolide Antibiotics Phenobarbital 
Tacrolimus Clarithromycin Phenytoin 
Benzodiazepine Erythromycin Anti-HIV agents 
Alprazolam Troleandomycin Efavirenz 
Midazolam Anti-HIV agents Nevirapine 
Triazolam Ritonavir Others 
Statins Saquinavir St. John`s wort 
Atorvastatin Indinavir  
Lovastatin Delaviridine  
Macrolide Antibiotics Others  
Clarithromycin Grapefruit Juice (Bergamottin)  
Erythromycin Mifepristone  
Anti-HIV agents Nefazodone  
Indinavir   
Nelfinavir   
Ritonavir   
Saquinavir   
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1.1.3. Drug-Drug Interactions 
 
A drug-drug interaction occurs when the effectiveness or toxicity of a drug is altered 
by the concomitant administration of another drug. Multiple drug therapy is common 
in some disorders and diseases and also in elderly patients.  Therefore, multiple drug 
therapy may increase the possibility of drug interactions (Hemeryck and Belpaire 
2003). In general, drug interactions can be attributed to pharmacodynamic and 
pharmacokinetic interactions (Reynolds 1990).  
Pharmacodynamic interactions:  Pharmacodynamic interactions occur when two 
drugs act at the same receptor sites, resulting in additive, synergistic or antagonistic 
effects (Reynolds 1990). 
Pharmacokinetic interactions: Pharmacokinetic interactions are attributed to the 
changes that occur in the absorption, distribution, metabolism or excretion of a drug 
and /or its metabolites when another drug or chemical agent is added to the treatment. 
Most commonly this occurs when one CYP is involved in the metabolism of both 
drugs (Reynolds 1990). 
 
1.1.4. Metabolic Drug-Drug Interactions 
 
Since hepatic CYPs are responsible for the metabolism of many drugs and they 
participate in metabolic pathways for several drugs, there is considerable potential for 
drug interactions. Most interactions occur when a particular CYP is involved in the 
metabolism of two different drugs that are co-administered (e. g. fluvoxamine and 
clozapine, which are both substrates for CYP1A2). Therefore, since most of the 
interactions occur with CYP enzymes, it is important to be aware of the CYPs that are 
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involved in the metabolism of particular drugs, and to avoid combination of 
medications that may interact with that CYP.  
 
 
Pharmacokinetic interactions caused by inhibition or induction of CYP activity are 
among the most common causes of drug interactions that may occur during 
polypharmacy. Metabolic interactions not only affect the plasma concentrations of 
drugs but also influence their efficacy and may also increase toxicity (Hemeryck & 
Belpaire 2003). Moreover, some drugs can induce their own oxidative metabolism 
and that of co-administered medications (e.g. certain steroid hormones and herbal 
products such as St. John’s wort increase the metabolism of orally administered drugs 
by increasing CYP3A4 levels (Madabushi et al 2006).  
 
Pharmacokinetic interactions caused by inhibition of CYP activity may occur when 
there are direct interactions between drugs that compete for the CYP. There are two 
basic types of inhibition mechanisms: reversible and irreversible. During irreversible 
inhibition, formation of a stable enzyme-drug complex leads to the loss of a CYP’s 
activity. The formation of this complex prevents the access of other drugs to the CYP 
enzyme. In this case, new enzyme must be synthesized for the restoration of CYP 
activity. The inhibitions of CYP3A4 by erythromycin and CYP2D6 by paroxetine are 
examples of this type of interaction (Tanaka 1998; Prior and Baker 2003). However, 
in reversible inhibition the activity of CYPs would be restored by clearance of the 
inhibitory agents (Prior and Baker 2003; Dailly et al 2002). This type of interaction is 
seen on co-administration of diazepam and omeprazole (Tanaka 1998). 
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The effect of enzyme induction is to increase CYP gene expression resulting in 
increased oxidation and clearance of a drug (Dailly et al 2002; Tanaka 1998). Since 
the activity of a particular CYP may be increased by exposure to an inducer drug, it 
may result in difficulty to maintain appropriate therapeutic effects without a dose 
increase (Tanaka 1998). 
 
The inhibition of CYPs in enterocytes of the intestinal epithelium may decrease the 
pre-systemic metabolism of some drugs. The activity of CYP3A4 in the intestine can 
influence drug bioavailability (Blume 2006). For example, felodipine is a CYP3A4 
substrate and is absorbed into the enterocytes of intestinal epithelium after oral 
administration. However, CYP3A4 in enterocytes metabolizes felodipine efficiently 
and only about 30% of a drug dose enters the portal vein. CYP3A4 in liver 
subsequently further metabolizes felodipine so that only 15% of a drug dose is 
actively available and can reach the systemic circulation. Thus, the inhibition of 
CYP3A4 in enterocytes may have significant effect on drug bioavailability 
(Wilkinson 2005). It is now established that bergamottin in grapefruit juice is a potent 
inhibitor of intestinal CYP3A4 (Wilkinson 2005). 
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1.1.5. CYP Pharmacogenetics and Metabolic Drug Interactions in Psychiatry 
 
Since monotherapy for psychiatric illness is rarely adequate, combination therapy is 
frequent but may increase the incidence of drug interactions (Strain et al 2004; Karow 
& Lambert 2003). Long term treatment for psychiatric illness also increases the 
potential for drug-drug interactions (Fleming & Chetty 2005). It has been reported 
that up to 4 medications may be used concurrently in the treatment of schizophrenic 
patients. Among the comedications, antidepressants, anxiolytics, and anticonvulsants 
are commonly prescribed (Rittmannsberger et al 1999). Some of the antidepressants 
are potent inhibitors and certain anticonvulsants are potent inducers of CYPs. 
Understanding the potential interactions is important so that clinicians may avoid 
toxicity or treatment failure.  
 
Furthermore, wide inter-individual differences due to polymorphic expression of the 
CYPs that are responsible for the disposition of antipsychotic agents influence both 
the efficacy and adverse effects of drug therapy in psychiatry (Vandel et al 2007). 
Differential expression of CYP alleles may influence efficacy and toxicity in a 
particular population. For example, expression of inactive variant alleles of CYP2D6 
is particularly important in psychiatric patients, due to its involvement in the 
metabolism of typical antipsychotics (such as, thioridazine and chlorpromazine), 
certain atypical antipsychotics (such as, risperidone) and the tricyclic antidepressants 
(Murray 2006). Moreover, CYP2D6 contributes to the metabolism of some 
endogenous compounds, such as neurotransmitters, which indeed may contribute to 
psychiatric and neurologic illnesses. However, more studies are now required to 
confirm this possibility (Vandel et al et al 2007).    
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 Table 1.6 indicates the principal allelic variant of CYPs that are involved in the 
metabolism of antipsychotic agents, and which may influence response to drug 
therapy.  
 
 
Table 1.6. Important genetic polymorphism of CYPs associated with clinical variations of 
response (Pirmohamed & Park 2003)  
 
P450 enzymes 
 
Variant 
 
Frequencies in Caucasians 
 
Clinical significance 
 
CYP1A2 
 
CYP1A2*1F 
 
68% 
 
High enzyme inducibility 
 
     CYP2C9 
  
 
CYP2C9*2 
CYP2C9*3 
 
8 to 13% 
7 to 9% 
 
Reduced enzyme activity 
Reduced enzyme activity 
 
CYP2C19 
 
 
CYP2C19*2 
CYP2C19*3 
 
13% 
0% 
 
Reduced enzyme activity 
Reduced enzyme activity 
 
CYP2D6 
 
 
 
CYP2D6*4 
CYP2D6*5 
CYP2D6*10 
CYP2D6*17 
 
12 to 21% 
4 to 6% 
1 to 2 % 
0% 
 
Reduced enzyme activity§ 
Reduced enzyme activity§ 
Reduced enzyme activity# 
Reduced enzyme activity# 
 
§, In Caucasians: CYP2D6 PMs are much more frequent. Four alleles *3, *4, *5, and *6 account 
for most (98%) inactive alleles (Bradford 2002). 
#, *10, which is frequent in Asians and *17, which is more frequent in blacks may have different 
activity for different drugs (de Leon et al 2006). 
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1.2. Schizophrenia and Drug Treatment 
 
 
About 1% of the world population is affected by schizophrenia, a severe psychiatric 
disorder (Kessler et al 1994). The pathogenesis of schizophrenia has not been fully 
explained. However, the dopamine hypothesis may contribute to the pathogenesis of 
schizophrenia as suggested by: I) Most antipsychotic agents potently antagonise 
dopaminergic receptors, particularly the D2 receptor. II) Drugs that increase 
dopamine activity such as amphetamine, levodopa, and apomorphine may exacerbate 
schizophrenia.  III) The density of dopaminergic receptors in the brains of 
postmortem untreated schizophrenics has been shown to be increased. IV) Positron 
emission tomography shows increased density of dopaminergic receptors in both 
treated and untreated schizophrenic patients compared to normal populations. V) The 
concentration of homovanillic acid (HVA), a metabolite of dopamine, is lower in 
patients who have been successfully treated for schizophrenia (Potter & Hollister 
2004).  
 
Schizophrenics exhibit positive and negative symptoms. The positive symptoms are 
associated with hallucination, delusion, agitation, and incoherent thought and speech. 
The negative symptoms include emotional withdrawal, apathy, attention impairment 
and anhedonia. Other symptoms such as anxiety, depression and cognitive impairment 
are also involved with schizophrenia (Chetty & Murray 2007).  
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Antipsychotic and neuroleptic drugs are used to treat schizophrenia and some other 
psychoses and agitated states. Antisychotic agents are classified into two general 
classes: the typical and atypical agents. 
A. Typical agents include phenothiazine derivatives (e.g. chlorpromazine, 
thioridazine), thioxanthene derivatives (e.g. thiothixene), and butyrophenone 
derivatives (e.g. haloperidol). 
B. Atypical antipsychotics include clozapine, olanzapine, quetiapine, risperidone, 
ziprazidone and aripiperazole (Potter & Hollister 2004).   
 
Chlorpromazine was introduced in the 1950s for the treatment of schizophrenia 
(Chetty and Murray 2007). After its introduction this agent decreased the morbidity 
and mortality due to schizophrenia (Chetty & Murray 2007). However, over the past 
decade the pharmacologic management of schizophrenia has changed so that now the 
atypical or second generation antipsychotics have become the first line of treatment 
because the neurological side effects are lower than those produced by the typical or 
first generation antipsychotics, such as phenothiazine, thioxanthene, and 
butyrophenone derivatives (Spina & de Leon 2007). The first generation of 
antipsychotics are extremely potent and produce a high incidence of extrapyramidal 
symptoms, such as tardive dyskinesia and dystonia. These may lead to the 
development of parkinsonian symptoms, such as tremor, rigidity and akathisia 
(Murray 2006). From a clinical perspective, the new generation of antipsychotics tend 
to have fewer extrapyramidal side effects and are broadly effective in treatment of 
both negative and positive symptoms of schizophrenia, while the first generation 
drugs are mainly effective against the positive symptoms of schizophrenia (Murray 
2006).  
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 Treatment with atypical antipsychotics is associated with increased risk of 
cardiovascular disease and metabolic disorders such as weight gain, hyperglycemia 
and lipid dysregulation. Different observations suggest that the increased risk of 
insulin resistance, dyslipidemia and hyperglycemia in patients treated with atypical 
antipsychotics is due to the weight gain during pharmacotherapy with these agents. 
However, limited controlled studies suggested that glucose dysregulation is a direct 
effect of clozapine and olanzapine treatment and independent of adiposity (Newcomer 
2005). Moreover, elevation of serum concentrations of liver enzymes has been 
reported in patients who have been treated with clozapine (Newcomer 2005).  
 
 
1.2.1. Typical Antipsychotics 
 
Chlorpromazine and haloperidol are among the major typical antipsychotics used for 
the treatment of schizophrenia. Chlorpromazine has a complex metabolic pathway 
and generates a range of metabolites. CYP3A4 is mainly responsible for oxidation of 
the heterocyclic sulphur of chlorpromazine (Cashman et al 1993). However, other 
CYPs such as 2D6 and 1A2 may also be involved in 7-hydroxylation and N-oxidation 
of chlorpromazine (Cashman et al 1993). An in vitro study showed that CYP2D6 is 
inhibited by chlorpromazine (Dayer et al 1992). The clearance of propranolol and 
debrisoquine were also impaired by chlorpromazine (Miller & Rampling 1982; 
Syvahlahti et al 1986). These findings support a role for CYP2D6 in chlorpromazine 
elimination. 
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Haloperidol is mainly metabolized by CYP3A4 and CYP2D6 to the N-dealkylated 
metabolite (Fang et al 1997). Co-administration of the antiepileptic agents phenytoin, 
phenobarbital and carbamazepine decreased plasma concentrations of haloperidol 
(Linnoila et al 1980). This is consistent with induction of CYP3A4 by the 
antiepileptic agents. Combined therapy with haloperidol and chlorpromazine has also 
been used recently in schizophrenic patients (Murray 2006), which may complicate 
the use of both drugs. Thus, the combination of chlorpromazine and haloperidol 
increased the serum concentrations of the latter, which was most likely due to the 
inhibition of CYP2D6 by chlorpromazine.  Suzuki et al reported that the plasma 
concentrations of haloperidol were higher in homozygous CYP2D6*1/*1 individuals 
than in those carrying the CYP2D6*5, PM genotype (Suzuki et al 2001). Thus, in 
addition to potential drug interactions, CYP2D6 genotype may also influence therapy 
with typical antipsychotics. 
 
 
1.2.2. Atypical Antipsychotics 
 
A major problem with typical antipsychotics is the failure of therapy in a substantial 
proportion of patients (termed treatment resistance). These drugs may be effective in 
the treatment of positive symptoms (such as hallucination and delusion), but in some 
cases they may worsen the negative symptoms (such as social withdrawal and 
avolition) (Karow and Naber 2002). Clozapine, olanzapine, quetiapine, risperidone, 
ziprasidone and aripiperazole are among the new generation of antipsychotic agents. 
However, despite the introduction of a number of different atypical agents, clozapine 
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is still the most effective treatment for refractory schizophrenia (Chetty & Murray 
2007). Figure 1.3 shows the chemical structure of atypical antipsychotics. 
 
 
 
 
Figure 1.3. Chemical structures of atypical antipsychotics (Murray 2006) 
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1.2.2.1. Clozapine 
 
Clozapine, the first atypical antipsychotic agent, is a piperidine derivative of the 
benzodiazepine family, which is mainly used in refractory schizophrenic patients 
and in patients who cannot tolerate the adverse effects of traditional 
antipsychotic treatment. Clozapine has many unique clinical advantages over the 
conventional antipsychotic agents. For instance, clozapine has a lower incidence of 
extrapyramidal side effects, such as tardive dyskinesia and dystonias. In addition, 
atypical antipsychotics such as clozapine are effective in both negative (such as social 
withdrawal and avolition) and positive (such as hallucination and delusion) signs of 
schizophrenia (Murray et al 2006). Agranulocytosis is one of the rare but serious side 
effects of clozapine that can lead to discontinuation of clozapine therapy (Baldessarini 
& Frankenburg 1991). Agranulocytosis was noted soon after the introduction of the 
drug and limited its usage for some time.  However, the incidence of agranulocytosis 
was decreased from 1% to 0.38%, as a result of compulsory homological monitoring 
via the Clozaril National Registry (Lieberman 1998). Despite the potential for 
agranulocytosis and other side effects such as orthostatic hypotension, sedation, 
seizure, and weight gain, the therapeutic advantages of clozapine outweigh its risks 
(Masellis et al 2000).   
 
 
 
1.2.2.1.1. Pharmacodynamics of Clozapine 
 
Most antipsychotic agents are antagonists for dopaminergic receptors, but also may 
have some affinity for other receptors such as α1 adrenoceptors, serotonin 5-HT2, 
 
 
 
 
 
26 
 
muscarinic, and H1 histaminic receptors. The clozapine antagonist affinity for 
different receptors is reportedly D4 = α 1 > 5-HT 2 > D2 = D1 (Potter & Hollister 2004).  
 
The relationship between clozapine concentration and therapeutic effect has been 
evaluated in numerous studies (Chetty & Murray 2007). There is a consensus that the 
minimum therapeutic plasma level of clozapine is 350-420 ng/mL (Chetty & Murray 
2007). Freeman & Oyewumi suggested a therapeutic range of about 400 ng/mL 
(1.2µM) to 1000 ng/mL (3.0 µM) for serum clozapine concentrations (Freeman & 
Oyewumi 1997). Some side effects such as weight gain, nausea, constipation, 
sialorrhea, hepatotoxicity, eosinophilia and akathisia appear to be unrelated to plasma 
concentrations of the drug, but other side effects appear to occur at plasma 
concentrations that exceed 1000 ng/mL (Chetty & Murray 2007). It has been reported 
that the risk of drowsiness, sedation, hypotension and seizure increases with increased 
clozapine plasma concentrations. It has been recommended that plasma 
concentrations should not exceed 1000 ng/mL (Chetty & Murray 2007).  
 
 
 
 
1.2.2.1.2. Pharmacokinetics of Clozapine 
 
Clozapine exhibits linear pharmacokinetics at therapeutic levels (Perry et al 1998; 
Doude van Troostwijk et al 2003a). The lipophilic clozapine is well absorbed after 
oral administrations and its variable bioavailability is not affected by food (Chetty & 
Murray 2007). Clozapine reaches maximum plasma concentrations (Cmax) after 1 to 
3.6 hours, elimination half-life (t1/2) is variable in the range 5.8 to 33 hours, total 
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plasma clearance is 37 to 55 L/h, and the volume distribution is 5 to 7 L/kg (Cheng et 
al 1998). Oral bioavailability of clozapine varies between 12 to 81% (Spina & de 
Leon 2007) and its high protein-binding exceeds 90 % (Cheng et al 1998). A study of 
15 psychiatric patients showed that the unbound fraction of clozapine in serum is 
about 5.5% and its renal clearance is 11% of the creatinine clearance (Schaber e al 
1998). 
 
The pharmacokinetic behavior of clozapine is subject to wide inter- and 
intraindividual variation.  Some important reasons for this variability include diet, 
age, disease, and CYP pharmacogenetics as well as the presence of exogenous 
inhibitors or inducers of CYPs that are involved in the metabolism of clozapine 
(Murray 2006; Dailly et al 2002).  Table 1.7 compares different pharmacokinetic 
parameters of atypical antipsychotics. 
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Table 1.7. Pharmacokinetic parameters of atypical antipsychotic agents (Spina & de Leon 
2007) 
 
  Bioavailability 
Protein 
Binding Half-life 
Time to 
reach 
Enzymes 
responsible Active metabolite(s) 
  (%) (%) (Hours) 
steady-state 
(days) 
for 
biotransformation   
Clozapine 
 
12 to 81 
 
>90 
 
6 to 33 
 
4 to 8 
 
CYP1A2, 
CYP2C19 
Norclozapine 
 
     
CYP3A4, 
CYP2D6 
FMO 
- 
 
 
Risperidone 
 
 
68 
 
 
90 
 
 
3 o 24 
 
 
4 to 6 
 
 
CYP2D6, 
CYP3A4 
 
9-hydroxyrisperidone 
 
 
Olanzapine 
 
60 to 80 
 
93 
 
20 to 70 
 
5 to 7 
 
CYP1A2, 
CYP2D6 
- 
 
     
UGT1A4, FMO 
  
Quetiapine 
 
NA 
 
83 
 
5 to 8 
 
2 to 3 
 
CYP3A4 
 
- 
 
Sertindole 
 
 
75 
 
 
99 
 
 
85 to 99 
 
 
15 to 20 
 
 
CYP2D6, 
CYP3A4 
 
- 
 
 
Ziprasidone 
 
 
60 
 
 
>99 
 
 
4 to 10 
 
 
2 to 3 
 
 
CYP3A4, 
aldehyde oxidase 
 
- 
 
 
Aripiprazole 
 
 
NA 
 
 
>99 
 
 
48 to 68 
 
 
14 
 
 
CYP3A4, 
CYP2D6 
 
Dehydro-aripiprazole 
 
 
Amisulpride 
 
43 to 48 
 
17 
 
12 
 
2 to 3 
 
Not clinically 
relevant 
-  
 
              
 
UGT, UDP-glucuronosyltransferases; FMO, flavin-containing monooxygenase-3 system. In bold the 
most likely to have clinical relevance. 
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1.2.2.1.3. Metabolism of Clozapine 
 
In man clozapine is extensively metabolized by N-oxidation to clozapine-N-oxide and 
N-demethylation to N-desmethylclozapine (norclozapine) (Dain et al 1997). Figure 
1.4 shows the major metabolic pathways of clozapine. An in vitro study has 
determined the relative contributions of CYP1A2, 3A4, 2C9, 2C19, and 2D6 to the N-
demethylation of clozapine at high and low (50 and 5 µM) concentrations of the drug 
in relation to the clinically relevant range for the concentrations found in liver (Olesen 
& Linnet 2001).  The results indicated that CYP1A2 was the major isoform involved 
in the formation of norclozapine at low concentration and made a 30% contribution to 
overall metabolism. CYP2C19 and CYP3A4 contribute 20% to 25%. However, at the 
higher concentration (50µM), CYP3A4 could be more important to norclozapine 
formation (37%). The contribution of CYP1A2 was 22%, which was still higher than 
the other CYPs. Importantly, however these studies were done in recombinant 
systems expressing single CYPs, which can significantly affect the findings. Study of 
CYPs in isolation (recombinant systems) is done with caution because findings in 
combination with other CYPs (e.g. in microsomes) can differ. This is due to the 
catalytic versatility of the enzymes, particularly in the absence of other competing 
CYPs. 
 
Several further studies have shown that CYP1A2 is the major enzyme involved in 
formation of norclozapine in microsomal fractions from human liver, while CYP3A4 
mainly contributes to formation of clozapine-N-oxide (Linnet & Olesen 1997; 
Pirmohamed et al 1995; Eiermann et al 1997; Tugnait et al 1999).  
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Studies in microsomes, rather than recombinant systems, probably provide a more 
accurate reflection of the situation that occurs in vivo.   
According to Bertilsson et al CYP1A2 activity is responsible for about 70% of the 
variation in oral clearance of clozapine (Bertilsson et al 1994). Variable response to 
antipsychotics such as clozapine could be explained by differential expression of 
CYP1A2 in schizophrenic patients (Ozdemir et al 2001). Caffeine is also a CYP1A2 
substrate and its conversion to paraxanthine may be used as a safe and convenient 
phenotypic marker for CYP1A2 activity. The correlation between caffeine and 
clozapine clearance indicates the importance of CYP1A2 to the metabolism of 
clozapine (Taylor 1997; Bertilsson et al 1994).  Moreover, it has been shown that the 
clozapine dose (mg/kg) is linearly related to the serum concentration of 
paraxanthine/caffeine (Doude van Troostwijk et al 2003a). In summary, in vitro and 
in vivo studies have established that CYP1A2 activity is an important factor in 
clozapine efficacy (Doude van Troostwijk et al 2003b). 
 
Figure 1.4. Metabolic pathway of Clozapine (Chetty and Murray 2007) 
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The evidence shows that CYP1A2 pharmacogenetics may affect clozapine 
metabolism. It has been shown that individuals who are homozygous for the CYP1A2 
allele that contains a CÆA SNP in intron 1 (CYP1A2*1F) exhibit ultrarapid activity. 
These patients are unresponsive to clozapine because of the failure to maintain 
adequate serum concentrations (Chin et al 2004; Ozdemir et al 2001). Further studies 
have shown that the efficacy of clozapine in ultrarapid metabolizers could be retrieved 
by concurrent treatment with fluvoxamine (50mg/d), which markedly inhibited 
CYP1A2 activity (Ozdemir et al. 2001). 
 
Carrillo et al have shown that the ratio of norclozapine/clozapine in plasma correlates 
with CYP1A2 activity as determined by urinary caffeine test in that study (Carrillo et 
al 1998). It was suggested that this ratio shows not only the importance of CYP1A2 
activity in clozapine clearance, but could also be a valuable estimate of CYP1A2 
activity in schizophrenic patients. Dailly et al used this ratio for determination of 
CYP1A2 activity and their findings were consistent with those of Carrillo et al (Dailly 
et al 2002). Thus, clozapine clearance and CYP1A2 activity, reflected by the 
norclozapine/clozapine ratio, were linearly related. This ratio could provide insight 
into the inter- and intra-individual variation of clozapine plasma concentrations, as it 
relates to CYP1A2 activity (Dailly et al 2002).  
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1.2.2.1.4. Pharmacokinetic Drug Interactions of Clozapine 
 
Treatment of refractory schizophrenia is long term and likely to include co-
administration of a number of other medications. Some of these medications are used 
to improve the clinical efficacy of clozapine or to reduce its adverse effects. Thus, 
concurrent therapy includes antidepressants, mood stabilizers, laxatives and proton 
pump inhibitors to prevent acid stomach. The risk of interaction increases during 
polypharmacy in schizophrenic patients (Chetty & Murray 2007).  
 
Clozapine: Interactions with CYP Inhibitors 
Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), has been reported to 
significantly impair clozapine clearance. The plasma concentrations of both clozapine 
and norclozapine increase during co-administration of fluvoxamine (Hiemke et al. 
1994; DuMortier et al 1996). Fluvoxamine increased the elimination half-life of 
clozapine from 17.3 to 50.6 hours (Wetzel et al 1998). Furthermore, patients may 
experience greater sedation or extrapyramidal side effects after addition of 
fluvoxamine to clozapine therapy (Kuo et al 1998). Fluoxetine, another widely used 
SSRI, also reportedly increased plasma clozapine concentrations up to 70% (Spina et 
al 1998). 
Although SSRI, and particularly fluvoxamine, may increase clozapine concentrations 
in serum to toxic levels, it has been suggested that the use of fluvoxamine could 
enable lower dose therapy with clozapine (Lammers et al 1999). In addition, the 
combination with fluvoxamine may improve the neuroleptic effectiveness of 
clozapine in clozapine-resistant schizophrenia (Silver et al 1996). 
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Ciprofloxacin and fluoroquinolone antibiotics increase clozapine plasma 
concentrations, by inhibiting CYP1A2 activity (Batty et al 1995; Raaska & Neuvonen 
2000).  Similarly, the CYP1A2 substrate caffeine also inhibits CYP1A2- dependent 
clozapine oxidation (Carrillo & Benitez 2000). Since schizophrenic patients have the 
habit of high coffee intake, it is important to determine the clinical significance of 
interactions between caffeine and clozapine. Evidence shows that caffeine increases 
clozapine concentration (Carrillo et al 1998). Hägg et al have shown that the oral 
clearance of clozapine decreases by 14% and its mean AUC (0, ∞) increases by 19% 
in presence of caffeine (Hägg et al 2000). An increasing number of reports of 
extrapyramidal side effects of clozapine due to ingestion of coffee or cola drinking is 
consistent with the suggestion that replacement with decaffeinated beverages could 
minimize such side effects (Vainer & Chouinard 1994). 
 
Valproate, a mood stabilizer agent, is usually administered to control seizures in 
schizophrenic patients who are on high doses of clozapine (Toth & Frankenburg 
1994). 
Findings of the effect of valproate on serum clozapine concentrations are 
controversial.  While some studies indicate that valproate decreases clozapine 
concentration by 51% or 15% (Finley & Warner 1994; Longo & Salzman 1995), 
others have reported increases of up to 39% (Centorrino et al 1994), or no effect 
(Facciola et al 1999).  
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Clozapine: Interactions with CYP Inducers 
Carbamazepine, an anticonvulsant that is sometimes co-prescribed with clozapine to 
control seizures, decreased serum concentrations of the drug up to 68% (Jerling et al 
1994). A case report showed that discontinuation of carbamazepine in two patients led 
to increases in serum concentrations of clozapine by 70%-100% (Raitasuo et al 1993). 
Apart from these pharmacokinetic interactions, the combination of carbamazepine and 
clozapine is not recommended due to an increased risk of neutropenia (Junghan et al 
1993).  
 
 Lane et al have reported that after discontinuing phenobarbital serum clozapine 
concentrations increased by 75% (Lane et al 1998). Another report indicated that 
inclusion of phenytoin in the medication profile of two patents who were receiving 
clozapine decreased plasma concentrations of the latter by 65 to 85% (Miller 1991). 
Similarly, the evidence shows that serum clozapine concentrations are lower in 
patients who are co-medicated with rifampicin (Wietholtz et al 1995).  Supporting this 
evidence, one forensic report indicated that clozapine concentrations were decreased 
in the presence of rifampicin. Replacement of rifampicin with ciprofloxacin increased 
serum concentrations of clozapine (Joos et al 1998). This may be due to the combined 
effect of removing CYP1A2 inducer and introducing a CYP inhibitor into therapy. 
 
 The average schizophrenic patient smokes 22.4 cigarettes per day, which is higher 
than the general population (Herran et al 2000). Several studies have indicated that the 
serum levels of clozapine in non-smokers are higher than in smokers (Seppala et al 
1999; van der Weide et al 2003).  
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de Leon performed a comprehensive study on the effect of smoking and caffeine 
on atypical antipsychotic dosing and suggested that the induction effect of 
smoking on CYP1A2 persists for at least two to four weeks (de Loen 2004). The 
separate effects of smoking and caffeine intake on clozapine therapy are 
summarized in Table 1.8 (de Leon 2004). Haslemo et al suggested that smoking 
of 7 to 12 cigarettes daily is sufficient to achieve maximal metabolism of 
clozapine and olanzapine metabolism. They also recommended that the dose of 
clozapine should be 50% higher in smokers in order to optimize therapy 
(Haslemo et al 2006).   
 
Sachse et al have suggested that the SNP (CÆA) in intron 1 of the CYP1A2*1F gene 
variant increases the inducibility of the gene (Sachse et al 1999). This study showed 
that smokers who possessed the homozygous genotype for the variant allele had 
approximately 1.6-fold higher CYP1A2 activity than either heterozygotes or 
individuals who were homozygous wild-type. However, in non-smokers, no 
significant differences in CYP1A2 activity were observed among the different 
genotypes (Sachse et al 1999).  Cessation of smoking in a patient who was 
homozygous for the CYP1A2*1F allele strongly increased serum clozapine levels up 
3004 ng/mL (Bondolfi et al 2005). It was also reported in that study that replacement 
of omeprazole, another established CYP1A2 inducer, by pantoprazole resulted in 
a very high plasma clozapine concentrations (Bondolfi et al 2005). In contrast, 
another study suggested that this variant of CYP1A2 has a lesser impact than 
smoking on clozapine clearance (van der Weide et al 2003). The ratio of 
clozapine plasma concentration/clozapine daily dose (C/D) was measured in 
homozygous and heterozygous patients carrying the *1F allele and in smoker and 
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non-smoker groups: the ratio of C/D for smokers with or without the A/A 
genotype were not significantly different (van der Weide et al 2003).   
 
 
Table 1.8. Recommended correction factors for smoking and using caffeine with 
clozapine 
 (de Leon 2004) 
 
Study 
 
Side Effects 
 
Recommended 
correction factor * 
Smoking with clozapine 
 
seizure; Antimuscarinic and sexual side 
effects 
1.5 
 
Using caffeine with 
clozapine 
Super ventricular tachycardia; Sedation 
 
0.6 
 
* Standard clozapine doses are multiplied by the recommended correction factor. 
 
Clozapine and omeprazole interactions: 
 It has been suggested that psychiatric illness could be associated with 
abnormalities of esophageal function (Clouse & Lustman 1983) and this 
necessitates treatment with a range of drugs. Recent studies have also suggested 
that clozapine therapy is associated with a number of gastrointestinal disorders, 
such as abnormal esophageal motility (Mc Carthy et al 1994), gastric reflux and 
gastro-oesophageal reflux (Laker & Cookson 1997). Therefore, concomitant use 
of clozapine and medication for treatment of gastrointestinal symptoms are 
frequently needed. Two case studies showed that in schizophrenic patients who 
responded poorly to conventional therapy, treatment with clozapine resulted in 
gastric discomfort. Endoscopy revealed moderate to severe (grade 3) reflux 
oesophagitis with erosions. Symptoms abated after lowering dosage or stopping 
clozapine therapy altogether, but recurred after completing the course of 
omeprazole treatment (Laker & Cookson 1997). 
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It has been reported that during omeprazole therapy with 40 and 60 mg/day in 
two schizoaffective patients, plasma clozapine concentrations were decreased by 
41.9% and 44.7%, respectively (Frick et al 2003). It was suggested that induction 
of CYP1A2 activity by omeprazole led to the decrease in serum clozapine 
concentrations (Frick et al 2003). Mookhoek et al showed that replacement of 
omeprazole by pantoprazole (a weaker CYP1A2 inducer) in 13 patients resulted 
in an increase in the mean clozapine and norclozapine levels in 3 non-smokers 
by 134 ng/mL and 117 ng/mL, respectively (Mookhoek & Loonen 2004). 
However, the small number of patients recruited in this study prevented a 
recommended dosage adjustment in cases where omeprazole was to be replaced 
by pantoprazole. 
Table 1.9 summarizes pharmacokinetic interactions associated with drugs that 
are used in combination with clozapine.   
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Table 1.9. Summary of pharmacokinetic interactions involving clozapine 
 
Interacting 
medications 
 
Proposed mechanisms 
  
Clozapine Carbamazepine Induction of CYP1A2, CYP3A4 and UGT Jerling et al 1994; Junghan et al 1993 
 Phenobarbital Induction of CYP1A2, CYP3A4 and UGT Lane et al 1998 
 Phenytoin Induction of CYP3A4 Miller 1991 
 Rifampicin Induction of CYP3A4 Wietholtz et al 1995 
 Omeprazole Induction of CYP1A2 Frick et al 2003; Mookhoek & Loonen 2004 
 Tobacco smoke Inducton of CYP1A2 deLoen 2004 
 Fluvoxamine Inhibition of CYP1A2 and, to a lesser extent, CYP2C19 and CYP3A4 Hiemke et al 1994; DuMortier et al 1996 
 Paroxetine Inhibition of CYP2D6 Spina et al 1998 
 Fluoxetine Inhibition of various CYP isoforms (CYP2D6, CYP2C19 and CYP3A4) Spina et al 1998 
 Ciprofloxacin Inhibition of CYP1A2 Raaska & Neuvonen 2000 
 
Valproate 
(controversial 
results) 
Enzyme inhibition? 
 
Centorrino et al 1994; Facciola et al 1999 
 
 Caffeine inhibition of CYP1A2 Carrillo & Benitez 2000 
    
 
 
 
 
1.2.2.2. Other Atypical Antipsychotics 
 
Olanzapine is an atypical antipsychotic agent that is structurally similar to clozapine 
in which one of the carbocyclic systems of clozapine has been replaced by a 
thiophene ring (Figure 4) (Murray 2006). The major metabolic pathways of 
olanzapine are N-glucuronidation mediated by UGT1A4 and N-demethylation 
mediated by CYP1A2 (Callaghan et al 1999). To a lesser extent, CYP2D6 and the 
flavin containing monooxygenase-3 are also involved in the metabolism of olanzapine 
(Callaghan et al 1999). Higher clearance rate and lower serum concentrations of 
olanzapine have been reported in smokers, which is consistent with an important role 
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for CYP1A2 (Carillo et al 2003). Concomitant use of olanzapine and fluvoxamine 
increased the serum concentrations of olanzapine and decreased in the clearance of 
the drug (Weigmann et al 2001). Because fluvoxamine inhibits CYP1A2, the clinical 
findings are also consistent with a role for the enzyme in olanzapine 
biotransformation.  
 
Risperidone undergoes approximately 70% first past hepatic extraction by CYPs.          
(Byerly & DeVane 1996). Risperidone is primarily metabolized by CYP2D6 to its 
active metabolite 9-hydroxyrisperidone; CYP3A4 may have a lesser role (Fang et al 
1999). It is reported that the affinity of 9-hydroxyrisperidone for the D2-dopamine 
receptor is similar to that of the parent drug (Spina & de Leon 2007). The genetic 
polymorphism of CYP2D6 may influence the therapeutic effects or the risk of side 
effects of risperidone. De Leon has suggested that the incidence of side effects leading 
to discontinuation of treatment with risperidone is greater in CYP2D6 PM subjects 
(de Leon et al 2005), while low serum concentrations of risperidone in UM subjects 
for CYP2D6, which may lead to treatment failure (Guzey et al 2000). Spina et al 
showed that cotherapy with the SSRI paroxetine, an inhibitor of CYP2D6, increased 
the serum concentrations of risperidone (Spina et al 2001).  Long term combination 
treatment of risperidone and fluoxetine, another SSRI that inhibits CYP2D6 and to 
lesser extent CYP3A4, decreased risperidone clearance and increased the incidence of 
parkinsonism, an adverse effect of risperidone (Spina et al 2002).    
 
The metabolism of Ziprasidone is complex. The major pathway is oxidation at sulfur 
to form ziprasidone-sulphoxide, ziprasidone-sulphone, and methyldihydroziprasidone 
(Prakash et al 2000). About two-thirds of ziprasidone metabolism is mediated by the 
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cytosolic aldehyde oxidase while CYP3A4, but not other CYPs, makes a minor 
contribution (Prakash et al 2000). Co-administration of the CYP3A4 inhibitor 
ketoconazole, decreased the clearance of ziprasidone and increased its serum 
concentrations (Miceli et al 2000).  Ziprasidone also inhibits CYP2D6 and CYP3A4 
in vitro (Wilner et al 2000).  
 
Quetiapine is primarily metabolized by CYP3A4, whereas CYP2D6 has a minor role 
(Murray 2006; DeVane & Nemeroff 2001). In a multiple dose study, concomitant 
administration of the CYP3A4 inhibitor ketoconazole increased quetiapine serum 
concentrations (Dev & Raniwalla 2000). Dose adjustments have been suggested 
during concomitant use of quetiapine and the CYP3A4 inducer phenytoin (Wong et al 
2001). 
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1.3. Proton Pump Inhibitors (PPIs): Pharmacology and 
pharmacokinetic Interactions 
 
Proton pump inhibitors (PPIs) are considered the most potent drugs of choice for the 
treatment of acid related disorders. Omeprazole, lansoprazole, pantoprazole, 
rabeprazole and esomeprazole are included in this class. From a clinical point of view, 
the newer PPIs (rabeprazole and esomeprazole) inhibit acid secretion with a faster 
onset that persists for longer than the older drugs in this class (omeprazole, 
pantoprazole and lansoprazole) (Robinson 2001).  
 
 
1.3.1. Physiochemical Properties  
 
Generally, PPIs are weak lipophilic bases that contain the pyridylmethylsulfinyl 
benzimidazole nucleus. Different substitutions on the pyridine or benzimidazole rings 
result in a small differences in their activity (Huang & Hunt 2001). Figure 1.5 shows 
the different chemical structures of PPIs. 
 
Figure 1.5. Chemical structure of PPIs (Li et al 2004) 
 
 
 
 
 
 
 
  R1          R2                                       R3                  R4                     X   
Omeprazole         CH3        OCH3                               CH3            OCH3 
Lansoprazole       H         OCH2CF3                         CH3            H          
Pantoprazole        H         OCH3                               OCH3         OCHF2 
Rabeprazole         H         OCH2CH2CH2OCH3       CH3            H 
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1.3.2. Indications 
 
The proton pump inhibitors, omeprazole, esomeprazole, lansoprazole, pantoprazole 
and rabeprazole, are the most effective antisecretory agents available for treatment of 
gastric acid related diseases. It has been established that PPIs are superior to earlier 
treatments for acid related disorders, such as antacid therapy, anticholinergic agents 
and H2 receptor antagonists (Robinsin 2004). PPIs are currently used for treatment of 
Peptic Ulcer Disease, Gastroesophageal reflux disease, Dyspepsia, Zollinger-Ellison 
Syndrome and Scleroderma oesophagus. The combination of antibiotics and PPIs is 
the key treatment for the eradication of H. Pylori. PPIs are also prescribed for acute 
upper gastrointestinal bleeding and prevention of acid aspiration (Kazung and Trevor 
2005). Furthermore, PPIs are used for prophylaxis of stress or peptic ulcer induced by 
Non-Steroidal Anti- Inflammatory Drugs (NSAIDs) (Blume et al 2006).  
 
 
1.3.3. Pharmacodynamics  
 
At least three types of receptors (histamine, gastrin and acetylcholine) on the parietal 
cell are involved in gastric acid secretion. Activation of any of these receptors can 
stimulate the H+, K+-ATPase (acid pump) which increases acid secretion. The gastric 
proton pump H+, K+-ATPase has a sulfhydryl group near the potassium-binding site 
on the luminal side of the canalicular membrane. The drugs are present as the ionized 
and non-ionized form in solutions, in ratios that are dependent on the pKa of drug and 
the pH of the solution. The neutral form of drug the may pass through lipophilic 
membranes and enter cells. From the Henderson-Hasselbach equation (pH= pKa + log 
[base]/ [acid]), the differences between drug pKa and intracellular pH determines the 
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extent of the lipophilic neutral form of the drug and its accumulation within the cell 
(Horn 2006). Once PPIs cross the parietal cell membrane into the highly acidic (pH 1) 
parietal cell canaliculus, they are protonated and therefore no longer lipophilic.  
Figure 1.6 shows the site of action of PPIs (Blume et al 2006; Williams & Pounder 
1999).  The active forms of omeprazole and other PPIs are the stable cyclic 
sulphenamides that bind covalently with sulfhydryl groups of the acid pump and 
irreversibly inhibit pump activity. The rate of conversion of the parent PPI drug to the 
sulphenamide at pH~1 is rapid and takes only 1.3-4.6 minutes. However, at a higher 
pH the rate of conversion is different for PPIs and ranges from about 7.2 minutes for 
rabeprazole to 1.4 hour for omeprazole (Kromer et al 1998). The higher pKa of 
rabeprazole of ~5 compared to omeprazole (~4) explains its more rapid onset and 
greater acid suppression. The extent and duration of intragastric acid inhibition 
associated with sulphenamide formation correlate with the healing rates of peptic 
ulcer and erosive oesophagitis and the control of acid related symptoms (Huang & 
hunt, 2001).  A meta-analysis has suggested that the rate of duodenal ulcer healing 
would be almost complete after 4 weeks if the pH was maintained at greater than 3 for 
18 hours (Burget et al 1990).  
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Figure 1.6. The site of action of PPIs (Blume et al 2006). 
 
 
 
 
 
Rabeprazole: rabeprazole has the same mode of action as the other PPIs, but due to 
different pyridine and benzimidazole substitution (Figure 1.5) it has a higher pKa. 
Therefore it undergoes a more rapid conversion to the sulphenamide form and also 
inhibits the H+, K+-ATPase more rapidly (Williams et al 1998). In addition, 
rabeprazole appears to dissociate more rapidly and completely from the H+, K+-
ATPase than either omeprazole or lansoprazole, which suggests that pump inhibition 
may be partially reversible (Huang & Hunt, 2001) although this remains to be 
established. Evidence indicates that rabeprazole achieves complete H+, K+-ATPase 
inhibition after 5 minutes, whereas 30 minutes is reported for omeprazole and 
lansoprazole, and pantoprazole achieves 50% inhibition after 45 minutes (Besancon et 
al 1997).  
 
According to a study in healthy Chinese volunteers, after the first dose of rabeprazole 
(20 mg) the mean AUC of rabeprazole was 80% of that measured after repeated 
dosing for 8 days (Hu et al 2005). This pharmacokinetic feature of rabeprazole 
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suggests that the maximum acid inhibitory efficacy of rabeprazole (pharmacodynamic 
effect) appears after one dose of the drug. A comparative study of the antisecretory 
effects of rabeprazole and omeprazole (20 mg dose) in H. pylori-negative subjects 
showed that, after single doses, the 24-h intragastric pH decrease with rabeprazole 
was more pronounced than with omeprazole. The results of this study have been 
summarized in Table 1.10 (Williams et al 1998). Another recent study reported that 
rabeprazole (20 mg) increased intragastric pH to ~ 3 to 4 for a longer period (24 
hours) than pantoprazole (40 mg) in patients with gastroesophageal reflux disease 
(GERD) (Warrington et al 2005). In vivo studies have shown that rabeprazole is more 
potent against H. pylori activity than omeprazole and lansoprazole. Thus, MIC50 and 
MIC90 of rabeprazole against eight strains of H. pylori were lower than those values 
for omeprazole and lansoprazole (Fujiyama et al 1994).   
It is recommended that some PPIs should to be taken before meal in order to inhibit 
proton pumps before they undergo activation by food (Horn 2006).  Table 1.11 shows 
the impact of food on the pharmacokinetics of PPIs (Horn 2006).   
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Table 1.10. Comparison of intragastric acidity/ pH and plasma gastrin on day 1 and day 8 of 
dosing with rabeprazole 20 mg and omeprazole 20 mg, once daily, in healthy H. pylori-
negative male volunteers (n=23) (Williams et al 1998) 
 
  Day 1   Day 8   
  
Rabeprazole 
20 mg 
Omeprazole 
20 mg 
Rabeprazole 
20 mg 
Omeprazole 
20 mg 
24-h  intragastric acidity 
(mmol.h/L) 
331* 
 
640 
 
160 
 
218 
 
24-h plasma gastrin (pmol.h/L) 
 
N/A 
 
N/A 
 
1687 * 
 
1085 
 
Median 24-h intragastric pH 
 
3.2 * 
 
2 
 
4.7 
 
4.2 
 
% time 24-h intragastric pH > 3 
 
55 § 
 
37 
 
69 ‡ 
 
60 
 
% time 24-h intragastric pH > 4 
 
44 § 
 
25 
 
59 ‡ 
 
51 
 
* ≤ 0.001, § < 0.01, ‡ < 0.05 vs. omeprazole 
 
 
 
 
Table 1.11. Effect of food on the  pharmacokinetics of PPI drugs (Horn 2006) 
       PPI 
 
Cmax 
 
Tmax
 
AUC 
 
Recommendation 
 
Esomeprazole -- -- ↓43-53% 1 h before food 
Lansoprazole ↓50-70% -- ↓50-70% Before food 
Omeprazole ↓25% ↑ ↔ Before food 
Pantoprazole ↔ ↑ ↔ with or without food 
Rabeprazole ↔ ↑ ↔ with or without food 
                     ↔ no effects, ↑ increase, ↓ decrease 
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1.3.4. Pharmacokinetics: Role of CYP2C19 Genotype 
 
PPIs have similar pharmacokinetic features, including rate of absorption, maximum 
plasma concentration, and total drug absorption (Li et al 2004). Table 1.12 
summarizes the pharmacokinetic parameters of common PPI drugs. 
All PPIs undergo hepatic oxidation usually mediated by CYP2C19 and CYP3A4. 
Figure 1.7 shows the major metabolic pathways of PPIs. 
The pharmacokinetics and pharmacodynamics of PPIs are related to CYP2C19 
genotype (Desta et al 2002). As mentioned in section 1.2, CYP2C19 (S-
mephenytoin 4´-hydroxylase) exhibits a large number of different polymorphic 
forms. Those who are deficient in the ability to metabolize S-mephenytoin are 
also deficient in PPI oxidation (Wedlund 2000). Moreover, recently it has been 
reported that CYP2C19 is responsible for the metabolism of about 80% of the 
PPIs omeprazole, lansoprazole and pantoprazole in EMs, while CYP3A4 may be 
more important in PMs (Desta et al 2002). The available evidence suggests that 
PMs recover better from gastric disorders compared with EM patients, 
presumably because of their lower capacity to clear PPIs (Furuta et al 2005).  
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Figure 1.7. The metabolic pathways of different PPIs (Ishizaki & Horai 1999) 
 
 
 
Table 1.12. Pharmacokinetic parameters of PPI drugs (Stedman & Barclay 2000) 
Pharmacokinetic 
parameters 
Omeprazole  
20 mg 
Pantoprazole 
40 mg  
Lansoprazole  
30 mg 
Rabeprazole  
20 mg 
AUC (µg.h/mL) 0.2 - 1.2 2 -5  1.7 - 5 0.8 
Cmax (µg/mL) 0.08 - 8 1.1 - 3.3 0.6 - 1.2 0.41 
Tmax (h) 1 - 3 2 - 4 1.3 - 2.3 * 3.1§ 
t1/2 (h) 0.6 - 1 0.9 - 1.9 0.9 - 1.6  1 
CL (L.h/kg) 0.45 0.08 - 0.13 0.2 - 0.28 0.5 
Vd (L/kg) 0.31 - 0.34 0.14 - 0.17 0.39 - 0.46  
Bioavailability 
(%) 
 
Variable 35-> 65 
(with repeated  
dose) 
Constant 
57 – 100 
 
Constant 
80 -91 
 
52 # 
 
Protein binding 
(%) 
95 
 
98 
 
97 – 99 
 
95 – 98 
 
Dose Linearity non-linear linear linear ‡ linear 
* Delayed to 3.5-3.7 with food, § delayed by 1.7 h with food, ‡ non-linear in some studies for 
doses < 20 mg and intravenous administration. #, Sclar et al 1994. 
 
AUC, area under the concentration-time curve; Cmax, maximum serum concentrations; Tmax, 
time to maximum serum concentration; t1/2, elimination half life; CL, drug clearance; Vd, 
apparent volume of distribution. 
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1.3.4.1. Metabolism of Omeprazole and Esomeprazole 
 
Omeprazole is almost completely oxidized to its two major metabolites, 5-hydroxy 
omeprazole and omeprazole sulfone, and no unchanged drug appears in urine or 
faeces (Howden 1991). Omeprazole is mainly metabolized by CYP2C19 and 
CYP3A4 to 5-hydroxyomeprazole and omeprazole sulfone, respectively. Also, 
CYP2C19 contributes to the formation of omeprazole sulfone (Anderson et al 1993). 
Figure 1.8 shows the major metabolic pathways of omeprazole. For most PPIs, such 
as omeprazole, the activity of CYP2C19 determines the plasma concentration of 
omeprazole (Rost et al 1992).  A recent study conducted by Klotz has shown that the 
AUC of omeprazole, lansoprazole, and rabeprazole are approximately 7.5, 4.5, and 4 
times higher in PMs than in homozygous EMs (Klotz 2006). The eradication rate of 
H. pylori is higher in PMs (100%) compared with EMs (29%) and IMs (60%) (Furuta 
et al 1998).  
 
The (S)-enantiomer of omeprazole is termed esomeprazole, which is metabolized 
slightly differently from racemic omeprazole and (R)-omeprazole (Miura et al 2005). 
Esomeprazole is also a substrate for CYP2C19 and CYP3A4, but its clearance is 
less affected by the CYP2C19 polymorphism than either the racemic form or (R)-
enantiomer (Miura et al 2005). Thus, CYP2C19 is responsible for 70% of 
esomeprazole oxidation, while 90% of (R)-omeprazole is metabolized by 
CYP2C19 (Abelo et al 2000).   Based on in vitro experiments, CYP2C19 and 
CYP3A4 account for approximately 70% and 30% of esomeprazole metabolites, 
respectively (Abelo et al 2000; Andersson et al 2001).  Additional in vitro 
studies of have also shown that the inhibitory potential of esomeprazole is low 
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and restricted to effects on the oxidation of CYP2C19 substrates (Abelo et al 
2000).  
 
 
 
Figure 1.8. Major metabolic pathways of omeprazole (Anderson et al 1993) 
 
 
 
 
 
1.3.4.2. Metabolism of Rabeprazole 
 
Some studies have suggested that the major metabolic pathway of rabeprazole is 
non-enzymatic reduction to the thioether (Figure 1.7) (Ishizaki & Horai 1999). 
Thus, the polymorphism of CYP2C19 appears to have a lesser impact on rabeprazole 
metabolism than on omeprazole metabolism (Horn 2006; Ishizaki & Horai 1999; Lim 
et al 2004). In contrast with other PPIs, Ariizumi et al have reported that after 4 or 8 
weeks treatment with 10 mg/day of rabeprazole, no significant differences in healing 
rate were seen among the different genotypes of CYP2C19 (Ariizumi et al 2006). 
However, it has been reported that the AUC of rabeprazole and its thioether 
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metabolite are significantly higher in PM than in EM subjects (Lin et al 2003). On day 
1 and 4 of treatment with rabeprazole (20 mg twice/daily), the AUCs for rabeprazole 
and its thioether metabolite were higher in PM than EM subjects. The plasma gastrin 
concentration was not different between PMs and EMs on day 1, but it was higher in 
PMs by day 4 (Lin et al 2003). These conflicting findings may relate to difference in 
the dosage regimens that were used in rabeprazole therapy but require independent 
confirmation in the future. 
The commercially available form of rabeprazole is the racemic mixture. Similar to 
other PPIs rabeprazole contains a chiral benzimidazole sulfoxide. The 
pharmacokinetic parameters of rabeprazole enantiomers in patients carrying three 
different CYP2C19 genotypes (homozygous EMs *1/*1, heterozygous EMs *1/*2 
and *1/*3 and PMs *2/*2) have been determined. The results showed that (R)-
rabeprazole produced higher plasma concentrations and higher AUC than (S)-
rabeprazole in all genotypes. Furthermore, the elimination half-life of (R)-rabeprazole 
was significantly longer in PMs than in homozygous EMs. Thus, it was suggested that 
clearance of the (R)-enantiomer of rabeprazole is more dependent on CYP2C19 
genotype than that of (S)-rabeprazole. However, the AUC ratios of R/S enantiomers in 
homozygous EMs, heterozygous EMs, and PMs (which were 1.8, 2.2, and 2.4) 
indicated that the overall metabolism of rabeprazole is less dependent on CYP2C19 
compared to lansoprazole (Miura et al 2005).  
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1.3.4.3. Metabolism of Lansoprazole and Pantoprazole 
 
Lansoprazole is metabolized by CYP2C19 and CYP3A4 to 5-
hydroxylansoprazole and lansoprazole sulphone, respectively. According to in 
vitro studies in human hepatic microsomes, the affinity of lansoprazole for 
CYP2C19 is lower than that of omeprazole (Furuta et al 2005).  Similar to 
omeprazole, lansoprazole induces the synthesis of CYP1A1 and CYP1A2 (Furuta 
et al 2005). Nevertheless, compared to omeprazole it does not appear to elicit 
clinically significant interactions with other drugs (Furuta et al 2005).   
 
Pantoprazole, like the other PPIs, undergoes hepatic oxidation by CYP2C19 and 
CYP3A4. All studies to date have suggested that the potential of pantoprazole to 
inhibit the activity of CYPs appears to be lower than that of omeprazole and 
lansoprazole (Simon et al 1991). 
Table 1.13 summarizes pharmacokinetic parameters of PPIs in subjects who are 
PM and EM for CYP2C19 (Ishizaki & Horai 1999).  
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Table 1.13. Pharmacokinetic parameters of PPIs in EMs and PMs of CYP2C19 (Ishizaki & 
Horai 1999). 
 
 t1/2 CL (ml/min/kg)     
PPIs 
 
EM 
 
PM 
 
EM 
 
PM 
 
AUCEM : AUCPM 
(0-∞) 
Cmax : Cmax PM 
 
Omeprazole 0.6 2.1 18.39 1.24 1.0 : 6.3 1.0 : 3.1 
 0.71 2.68 1.24 0.06(L/h/kg) 1.0* : 3.7§ : 20.0‡ 1.0* : 2.6§ : 7.6‡ 
       
Lansoprazole 1.4 3.2 0.26(L/h/kg) 0.04(L/h/kg) 1.0 : 4.7 1.0 : 2.4 
 
1.9* 
 
3.61 
 
3.77 
 
0.78 
 
1.0*: 1.92§ : 4.11‡ 
 
1.0*: 1.32§ : 1.88‡ 
 
Pantoprazole 1.4 6.9 125.5  20.19  1.0 : 6.0 1.0 : 1.7 
   (mL/min) (mL/min)   
       
Rabeprazole 1 1.8 8.94 3.9 1.0 : 1.8 1.0 : 0.97 
       
   *Homozygous EMs, § Heterozygous EMs, ‡PMs 
 
 
 
 
 
1.3.5. Interaction Profiles of PPIs 
 
Since most of the gastric acid-related disorders are chronic, long term treatment seems 
necessary and consequently the likelihood of concomitant use of other drugs is 
increased (Blume et al 2006). Three types of interactions are common with PPI drugs:  
1) Increasing gastric pH, 2) Interaction with the P-glycoprotein transporter protein and 
3) interaction with CYPs.  
 
 
1.3.5.1. Modulation of Gastric pH 
 
Since PPIs increase gastric pH, they could modify the extent of ionization, solubility 
and the release of certain drugs (Blume et al 2006). Ketoconazole and itraconazole are 
two important drugs that are susceptible to this type of interaction (Chin et al 1995; 
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Jaruratanasirikul & Sriwiriyajan 1998). Increased gastric pH decreases the solubility 
of the drugs in aqueous systems. After co-administration of omeprazole the AUC of 
ketoconazole and itraconazole is reduced by 80% and 64%, respectively (Chin et al 
1995; Jaruratanasirikul & Sriwiriyajan 1998). It seems that most of the significant 
interactions reported with rabeprazole are a result of increased gastric pH, e.g. with 
digoxin and ketoconazole. Gastric acid antisecretory effect of rabeprazole may 
increase intra-gastric pH and decrease the absorption of digoxin and ketoconazole 
(Blume et al 2006).    
 
 
1.3.5.2. Interactions with the P-glycoprotein Transporters 
 
P-glycoprotein transporters mediate the efflux of some drug substrates from 
enterocytes back into the gut lumen, or from the capillaries of the blood-brain 
barrier back into the blood stream (Potschka et al 2001).  
P-glycoprotein inhibitors or inducers can affect the disposition of transporter 
substrates (Potschka et al 2001). It has been suggested that P-glycoprotein 
transporters might affect the access of some drugs to CYP3A4 present in the intestine 
(Blume et al 2006). PPIs, such as omeprazole, lansoprazole, and pantoprazole are 
substrates of this transporter system and have been reported to inhibit P-glycoprotein 
mediated efflux of digoxin (Paul-Magnus 2001).  
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1.3.5.3. Interactions with CYP Enzymes 
 
Recent in vitro studies of the inhibitory effect of PPIs on four CYPs (CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4) have shown that none of the drugs inhibited 
CYP2D6. However, CYP2C9, CYP3A4, and CYP2C19 are susceptible to 
inhibition by PPIs (Li et al 2004).  
The inhibitory potency of PPIs toward CYP2C19 was determined in both human 
liver microsomes and with recombinant CYP (rCYP). In microsomes the 
inhibition constant (Ki) of omeprazole against CYP2C19 was between 2 and 9 
µM and was between 17 and 21 µM for rabeprazole. Interestingly, the thioether 
metabolite of rabeprazole was more potent than the parent drug against 
CYP2C19 (Ki = 2-8 µM) (Li et al 2004). Moreover, omeprazole and rabeprazole 
were relatively non-potent inhibitors of CYP3A4, but the inhibitory potency of 
rabeprazole thioether was about 3-fold higher than that of rabeprazole (Ki = 41.9 
µM for omeprazole; Ki = 50.7 µM for rabeprazole and 15 µM for rabeprazole 
thioether) (Li et al 2004).   
 
 
 
1.3.5.3.1. Inhibition of CYP-dependent Drug Oxidation by Omeprazole 
 
CYP2C19 mediates the formation of the major metabolite of diazepam, which is 
N-desmethyldiazepam (Anderson et al 1990). Although many factors in vivo 
could influence the inhibition of diazepam metabolism, it has been confirmed 
that the clearance of diazepam is reduced up to 25% to 50% during concomitant 
use of omeprazole, due to competitive inhibition of CYP2C19 (Caraco et al 
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1995). Another study indicated that omeprazole does not impair the clearance of 
diazepam in PMs for CYP2C19, but in EMs the clearance of diazepam is 
impaired (Ishizaki et al 1995). In agreement with this finding Andersson et al 
have reported that omeprazole only decreases the clearance of diazepam in 
CYP2C19 EM subjects (Andersson et al 1990). 
 
Omeprazole was shown to reduce the clearance of both carbamazepine and 
phenytoin (Dixit et al 2001; Prichard et al 1987) 
Phenytoin is principally metabolized by CYP2C9 to 5-(p-hydroxyphenyl)-5-
phenylhydantoin (p-HPPH) and also by CYP2C19 (Levy 1995). Omeprazole 
increases phenytoin plasma concentrations by about 25% due to the inhibition of 
CYP2C19 activity (Richard et al 1987).  
CYP3A4 is the main enzyme involved in the metabolism of carbamazepine to 
carbamazepine-10, 11-epoxide (Levy 1995).  Dixit et al demonstrated that 
multiple doses of omeprazole increased the Cmax, AUC, and elimination half-
life of a sustained-release preparation of carbamazepine (Dixit et al 2001). 
 
Since omeprazole is a competitive inhibitor of CYP2C19 and this enzyme oxidizes 
warfarin to some extent, the metabolism of warfarin might be altered during 
omeprazole therapy. However, findings in this regards are conflicting (Blume et al 
2006). Some studies have demonstrated that the hepatic metabolism of the R-
enantiomer, but not the S-enantiomer, of warfarin is inhibited due to CYP2C19 
inhibition. However, only one of these studies demonstrated a significant increase in 
the anticoagulation time of warfarin (Blume et al 2006). Thus, the clinical 
significance of the interaction is unclear. 
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CYP2C19 is an important enzyme in the bioactivation of the antimalarial prodrug 
proguanil, to cycloguanil. An in vitro study has shown that omeprazole (20 µmol/L) 
inhibits cycloguanil formation (Funck-Brentano et al 1997). Following an in vivo 
study in healthy subjects, the apparent oral clearance and metabolic clearance of 
proguanil to cycloguanil decreased significantly in the presence of omeprazole 
(Funck-Brentano et al 1997).  
 
Omeprazole (40 mg) also inhibited the metabolism of moclobemide, an antidepressant 
with selective action at monoamine oxidase-A, that is principally a substrate for 
CYP2C19. Omeprazole inhibited moclobemide metabolism in CYP2C19 EM subjects 
but not in PM subjects (Yu et al 2001). 
 
 
 
1.3.5.3.3. Induction of CYP Genes by Omeprazole 
 
Studies in cultured cells have indicated that CYP1A1 and CYP1A2 mRNA expression 
is increased by omeprazole (Shin et al 1999; Quattrochi & Tukey 1993; Curi-Pedrosa 
et al 1993). Subsequent in vivo studies of caffeine clearance in breath or urine 
confirmed the induction of CYP1A2 by omeprazole. However, most of these studies 
have indicated that the induction of CYP1A2 is dose dependent.  A study conducted 
on 12 EM, one intermediate metabolizer, and 5 PM for CYP2C19 (Rost et al 1992), 
using the 13C-caffeine breath test, showed that the AUC of omeprazole after 7 days 
treatment with 40 mg omeprazole was 4-fold higher in the PMs than in the EMs for 
CYP2C19. Also, the exhalation of 13CO2 was significantly higher in PMs and 
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intermediate metabolizers than in the EMs.  Thus, it appears that CYP1A2 induction 
at therapeutic dose of omeprazole (40 mg/daily) is dependent on CYP2C19 status. 
Another study by the same authors showed that CYP1A2 induction by omeprazole in 
EMs is dose-dependent (Rost et al 1994). Thus, CYP1A2 activity was increased only 
8.5% by 40 mg omeprazole and 27.3% by a 120 mg dose. Furthermore, it has been 
suggested that omeprazole does not induce CYP1A2 activity at conventional 
therapeutic doses (20 mg/day) (Andersson et al 1998; Rizzo et al 1996; Sinues et al 
2004).  These findings indicate that the in vivo induction of CYP1A2 is dependent on 
the plasma concentration of omeprazole as well as CYP2C19 status (which influences 
the elimination of omeprazole). Moreover, it has been suggested that the induction of 
CYP1A2 by omeprazole may depend on the CYP1A2 genotype. An in vivo study with 
12 subjects who were EMs with respect to CYP2C19 showed that the plasma  ratio of 
caffeine/paraxanthine metabolite (used to reflect CYP1A2 activity) was significantly 
higher in subjects who were homozygous for CYP1A2*1F after 7 days treatment with 
omeprazole (120 mg daily) (Han et al 2002).  As mentioned previously, the 
CYP1A2*1F genotype appears to be a more inducible allele (Sachse et al 1999).  
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1.3.5.3.3. Inhibition of CYP Enzymes by Rabeprazole 
 
 
Recent study has shown that fluvoxamine, which is a potent CYP2C19 inhibitor, 
increases the AUC of rabeprazole and its thioether metabolite by 2.8-fold and 5.1-fold 
in homozygous EMs and 1.7-fold and 2.6-fold in heterozygous EMs, respectively 
(Uno et al 2005). Rabeprazole thioether may be demethylated by CYP2C19. Shirai et 
al have shown that the AUC of rabeprazole was not changed after repeated doses of 
rabeprazole in individuals with different CYP2C19 status. However, the AUC of 
rabeprazole thioether was significantly higher in CYP2C19 PMs (Shirai et al 2001). 
Although, rabeprazole itself may not influence CYP2C19 activity significantly, its 
thioether metabolite may be an inhibitor of the enzyme. Further studies will be useful 
to corroborate this possibility and then evaluate its effects on pharmacokinetics of co-
administered drugs.  
 
 
1.3.5.3.4. Induction of CYP Genes by Rabeprazole 
 
Krusekopf et al have investigated the induction of omeprazole and rabeprazole on 
CYP1A1, 1A2 and 1B1 activity in HepG2 cells. After 4 hours treatment of HepG2 
cells with omeprazole (100 µM) and rabeprazole (50 µM), both omeprazole and 
rabeprazole induced CYP1A1 and CYP1A2. Omeprazole was a more effective 
inducer (Krusekopf et al 2003). No other studies have yet evaluated the effect of 
rabeprazole on the activities of CYP1A2 or other CYPs. Further understanding of the 
effect of rabeprazole on CYP function and expression may assist dose prediction and 
adjustment of drug such as clozapine. Table 1.14 summarizes the clinically significant 
interactions of omeprazole and rabeprazole with antipsychotic agents 
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Table 1.14. Interactions of omeprazole and rabeprazole with antipsychotics and other drugs. 
 
Drug Major P450 
involved 
Omeprazole Rabeprazole References 
Diazepam 
 CYP2C19 
Clearance No 
interaction Caraco et al 1995 
Phenytoin 
 CYP2C9/2C19 
Clearance Unknown Richard et al 1987 
Carbamazepine 
 
CYP3A4/ 
P-glycoprotein 
Clearance Unknown Dixit et al 2001; Prichard et al 1987 
Clozapine 
 CYP1A2 
Clearance Unknown Frick et al 2003; Mookhoek & Loonen 2004
Olanzapine 
 CYP1A2 Unknown Unknown www.nzhpa.org.nz 
Triazolam 
 CYP3A4 
Clearance Unknown Blume et al 2006 
Warfarin 
 CYP2C19 
Controversial 
results Unknown Blume et al 2006 
Proguanil 
 CYP2C19 
Clearance Unknown Funck-Brentano et al 1997 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
1.4. Aims of this study 
 
The replacement of omeprazole with rabeprazole may offer therapeutic benefits 
in clozapine patients who require PPIs. However, to date there have been no in vivo 
studies that have evaluated the impact of rabeprazole on clozapine metabolism. The 
major aim of this study was to investigate and compare the effects of rabeprazole and 
omeprazole on plasma clozapine concentrations and therefore on apparent clozapine 
clearance in patients. Hence, the hypothesis of this research is that “Does rabeprazole 
has a similar effect as omeprazole on apparent clearance of clozapine?” 
Therefore, the effect of the PPI-clozapine combinations on plasma clozapine 
concentration was assessed in sequential fashion in patients who were controlled by 
clozapine. 
 
The results may assist the evaluation of the influence of rabeprazole on CYP1A2 
activity, which is the most important enzyme in the metabolism of clozapine.   
 
Because there are a number of potential covariates that could influence clozapine 
plasma concentrations, these variables were considered in the present analysis. Apart 
from CYP1A2 function these patient covariates included cigarette smoking, weight, 
Body Mass Index (BMI), age, and gender.  
 
A model for clozapine pharmacokinetics was evaluated using the Abbottbase 
Bayesian Pharmacokinetic System (PKS) and internal and external data. 
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CHAPTER TWO: 
MATERIALS AND METHODS 
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2. Materials and Methods  
 
2.1. Study Subjects 
 
The study was approved by the Northern Sydney Health Human Research Ethics 
Committee and University Human Ethics Committee. Patients from Macquarie 
Hospital who were stabilized on clozapine were recruited for this study. These 
subjects were also receiving rabeprazole as part of their drug therapy for clozapine 
mediated gastrointestinal disturbances. They were not receiving other medication that 
could potentially interact with CYP1A2 and CYP2C19 (Appendix I).  Enrolled 
patients did not have any coexisting medical conditions (such as renal impairment). 
Although cigarette smoking has been shown to induce CYP1A2 (Bondolfi et al 2005), 
smokers and non-smokers subjects were included in this study since the majority of 
schizophrenic patients are smokers (Ücok et al 2004). 
 
The study was conducted over a period of 5 months. Relevant medical staff in the 
rehabilitation wards discussed the study with patients who were eligible for inclusion 
in this clinical trial. Patients who were willing to participate were provided verbal and 
written information (Appendix II) about the study, and written informed consent was 
obtained from each participant (Appendix III). Of the eligible patients all but one 
were happy to participate. Medical staff in the rehabilitation wards (Psychiatrists in 
charge, chief pharmacist and registered nurse) supervised enrolment and took blood. 
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To provide privacy and confidentiality for the enrolled patients all information was 
identified by patient codes and not by name. 
 
Details required for population pharmacokinetic analysis such as demographics, 
dosing schedule, smoking and alcohol histories, and concurrent medication were 
obtained from the hospital files of the study patients at the Macquarie Hospital. 
Approximately 80% of all schizophrenic patients in hospital who received clozapine 
were smokers. Data on number of smoked cigarettes are recorded and controlled by 
nurses. Finally, 20 patients were recruited to this study. The student obtained the 
patient data and blood samples for analysis. The patients’ data are presented in table 
2.1.  
 
 
2.2. Study design 
 
A cross-over study design was used to compare the effects of co-administered 
rabeprazole and omeprazole on plasma clozapine concentrations in patients. Twenty 
patients who had been receiving clozapine and rabeprazole (with no other interacting 
medications) for at least two weeks and were at steady state were recruited into the 
first arm of the study (Phase 1). Clozapine dosage was determined by the attending 
clinician and the dose of rabeprazole was either 20 mg or 40 mg. Blood samples (10 
ml each) were taken 30 minutes, 1 hour, 2 hours and 12 hours after a dose of 
clozapine.  
In the second arm of the study (Phase 2), rabeprazole was switched to omeprazole 
(consistent with the rabeprazole dose in the first arm of the study i.e. 20 or 40 mg).  
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Samples were again collected at the intervals described above after the patients had 
received omeprazole and clozapine for at least one month. Table 2.1 summarizes 
these phases of the study. 
Recruitment to the proposed control was not possible because patients were not 
available. Further, technical issues prevented the assay of the 5-hydroxy- metabolite 
of omeprazole in patient samples. 
 
Table 2.1: Phase I and Phase II of the study 
 
Phase I Phase I Phase II Phase II 
Clozapine + Rabeprazole 
(at least 2 weeks) 
Time at which 
blood samples 
were taken 
relative to last 
dose 
 
Clozapine + Omeprazole 
(1 month) 
Time at which 
blood samples 
were taken 
relative to last 
dose 
 
30 min 30 min 
1hr 1hr 
2hr 2hr 
 
12hr 
 
12hr 
 
 
Blood samples from the patients were collected into heparinized tubes. Immediately 
after collection, blood samples were centrifuged (2000g x 10 minutes). The obtained 
plasma was stored in 1.5 mL Eppendorf tubes at -80˚C until used in assays. The 
interval between sampling and assays was 5 to 6 months. Aravagiri & Marder 2001 
have shown that clozapine and its metabolites (norclozapine and clozapine-N-oxide) 
stored in freezer at -70 °C are stable over a period of 6months (Aravagiri & Marder 
2001).  
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Clozapine and norclozapine concentrations were estimated (described in section 2.3 
of Materials and Methods). The clozapine concentrations were used to determine the 
pharmacokinetic parameters of clozapine, and the ratios of norclozapine/clozapine at 
trough levels were used to reflect CYP1A2 activity in the presence of rabeprazole in 
phase 1 and in the presence of omeprazole in phase 2. Statistical analysis was 
performed using GraphPad Prism (Version 4.00). 
 
2.3. Analytical Method 
 
The concentrations of clozapine and norclozapine were quantified by a high-
performance liquid chromatography (HPLC) at the Austin and Repatriation Medical 
Centre in Heidelberg, Victoria. The frozen plasma samples were transported to 
Melbourne on dry ice by Australian Air Express. 
 
 A liquid-liquid extraction method was used to extract clozapine and norclozapine 
from plasma. To 0.5 mL of plasma, 10 µL of internal standard (flunitrazepam, 5 
mg/mL in methanol) was added. Clozapine and norclozapine were extracted by the 
addition of hexane (2.5 mL) and ethyl acetate (2.5 mL) and the sample was vortex 
mixed for one minute and then centrifuged (1000g x 5 min). The aqueous layer was 
frozen in a chilled ethanol bath at -30˚ C and the organic layer was transferred to a 
clean labeled tube. Samples then were dried under a stream of air before 
reconstitution in mobile phase (150 µL) and injection (20 µL) on to a Spherisorb CN 
5 µm 0.5 x 150 mm column (Alltech). Separation was achieved using a mobile phase 
of 60:40, acetonitrile: triethylamine (2.2 mmol/L, pH 5.5-6 adjusted with 
orthophosphoric acid) at a flow rate of 1.5 mL/min and detection at 254 nm. 
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Multipoint standard curves were constructed from clozapine (47, 94, 188, 375, 750 
and 1500 ng/mL) and norclozapine (94, 188, 375 and 1500 ng/mL). The lower limit 
of quantitation for clozapine was 47 ng/mL and for norclozapine was 94 ng/mL. The 
upper limit of quantitation was 1500 ng/mL for both clozapine and norclozapine. 
 
The inter-day accuracy and precision were assessed at low, medium and high 
concentrations across the standard curve and were <12.2% and <8.5% for clozapine 
and < 19.1% and <12.3% for norclozapine, respectively. The coefficients of 
determination (r2) for standard curves were >0.995 in all cases. 
 
 
2.4. Estimation of Clozapine Clearance 
 
The Abbottbase Pharmacokinetic System (PKS) Software Version 1.10 (Abbott 
Laboratories, Abbott Diagnostics GMBH), was used to estimate the pharmacokinetic 
parameters of clozapine in the study participants by Bayesian forecasting.   
Statistical analysis was performed using GraphPad Prism (Version 4.00). 
 
 
 
2.4.1. Bayesian Model for Estimation of Pharmacokinetic Parameters of 
Clozapine Using Abbottbase Pharmacokinetic System (PKS) 
 
PKS software allows the user to predict drug dose, calculate population 
pharmacokinetic parameters and estimate their variability.   
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The model was validated using concentration-time data from patients in another study 
(obtained by personal communication with researchers). 
 
The values for development of a Bayesian model for clozapine were extracted from 
the literature (Doude van Troostwijk et al 2003b) and were as follows:  
 
Vd (volume of distribution) = 6±21 L/kg 
Ke (elimination rate constant of clozapine) = 0.05±0.02 h-1  
 F (bioavailability) = 0.34±0.12  
Ka (absorption rate constant) = 1±0.5 h-1         
(Parameters used in the model of Doude van Troostwijk et al (2003b) were derived 
from three sources, Guitton et al 1998, Jann et al 1993, Miller et al 1994). 
   
Doude van Troostwijk et al (2003b) used population PK software (MWPharm) and 
Bayesian analysis to estimate PK parameters of clozapine. The estimated PK-
parameters in that study were obtained using single blood samples. In the present 
study at least four points were used to estimate PK-parameters of clozapine, which 
leads to more accurate estimations. Figure 2.1 shows the model set up panel of the 
PKS for clozapine. 
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Figure 2.1: Input data for validation of Abbottbase Pharmacokinetic System (PKS) for 
clozapine  
 
 
 
The predicted concentrations, apparent clearance (CL/F) and apparent volume of 
distribution (Vd/F) of clozapine in both phases of the study were calculated by the 
PKS program after entering the actual concentrations of clozapine in individual 
patient samples taken at the indicated times after dosage (0.5, 1, 2 and 12 hr).  The 
calculated clearance and volume of distribution data in this thesis are apparent 
clearance (CL/F) and apparent volume of distribution (Vd/F). 
 
There are different methods for evaluation of the performance of Abbottbase 
Bayesian model: 
1. Correlation between the observed and predicted plasma concentrations.   
The bias (accuracy) is calculated by Mean Prediction Error (ME) and precision is 
calculated by Mean Square Error (MSE) or Root Mean Square Error (RMSE) 
(Sheiner & Beal 1981).   
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2. Correlation between the observed and predicted area under the curve (AUC). 
 
 For evaluation of the performance of the program the actual plasma concentrations of 
clozapine were plotted against the predicted plasma concentrations at all sampling 
time points in both phases of the study. In addition, the AUC0-12 of clozapine was 
calculated by the log trapezoidal method, in which the actual and predicted clozapine 
concentrations were entered. The ME and RMSE indicated bias and precision of this 
software.  
 
The accuracy and precision of the developed model were also estimated using the 
external data on 38 subjects derived from the dataset taken obtained in another study 
(by personal communication with researchers). External model evaluation was 
performed by plotting the actual and predicted plasma concentration-time curve at 
trough level of clozapine.  The ME and RMSE indicated bias and precision of this 
software.  
 
 
2.5. Statistical analysis: 
 
All the statistical analyses were performed using GraphPad Prism (Version 4.00).  
The comparison of the clozapine clearance in the presence of rabeprazole and 
omeprazole was performed using the two-tailed paired student’s t-test.  
The influence of smoking on clozapine clearance was performed using one-way 
analysis of variance.  
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Pearson r test was performed to determine the correlation between both clozapine 
clearance and weight and BMI. The same statistical approach was used to determine 
the correlation between the ratio of plasma norclozapine/clozapine concentrations and 
weight and BMI. 
 Mann-Whitney test was applied to compare clozapine clearance in male and female 
and in two groups of patients with BMI>25 and BMI<25 in phases of the study. 
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CHAPTER THREE: 
RESULTS 
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3. Results 
 
3.1. Subjects 
 
Twenty patients were recruited in this study (Table 3.1). The demographic 
characteristics of the 20 evaluable patients are summarized in table 3.2.  Fifteen males 
and five females were recruited in this study. Ninety percent of recruited patients were 
Caucasians. The ages ranged from 22 to 67 years (mean ± SD: 43.74 ± 14.39), the 
heights were in the range of 159 to 188 cm (mean ± SD: 173 ± 8.95), weights ranged 
from 60 to 128 kg (mean ± SD: 89.37 ± 18.57) and the Body Mass Index (BMI) 
values were from 22 to 39.5 (mean ± SD: 29.61 ± 5.60). Since 80% of admitted 
schizophrenic patients to hospital were smokers, just four nonsmokers could be 
recruited in this study and 16 patients were smokers. The daily dose of clozapine 
among the patients varied between 2.8 to 11.8 mg/kg/day (mean ± SD: 6.1 ± 2.33). 
The PPI dosage was either 20 or 40 mg/day. The clozapine and norclozapine plasma 
concentrations were assayed in samples collected from the patients at 0.5, 1, 2 and 12 
hours after clozapine intake during both phases of the study. The trough level for one 
patient was not determined because of sample losses during HPLC. The comparisons 
involving the trough levels, particularly the plasma ratio of norclozapine/clozapine 
concentrations of this patient was omitted from the analysis. In addition, a 2 hour 
sample for one of the patients was not available in the second phase of the study.  
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Table 3.1: patients’ data 
Patient Sex Weight Height Age  BMI Cigarettes Clozapine Dosage (mg) PPI 
  kg cm Year  /day  (mg) 
MN-1 M 128 180 38 39.5 20 200m/500n 20 
GR-2 M 69 177 55 22.0 14 100m/200n 20 
MS-3 M 107 187 32 30.6 25 300m/400n 20 
RE-4 M 68 173 52 22.7 Nil 400m/400n 20 
DD-5 M 103 187 44 29.5 Nil 200 (13pm) / 350n 20 
TE-6  M 68 175 67 22.2 Nil 350m/350n 40 
PN-7 F 60 164 65 22.3 8 150m/250n 20 
GH-8 M 84 166 51 30.5 20 50 (14pm) /400n 20 
AI-9 M 101 188 31 28.6 30 150m/300n 20 
FE-10 M 106 175 28 34.6 20 50m/400n 20 
KN-11 M 86 185 26 25.1 15 100m/400n 40 
DR-12 M 106 175 27 34.6 15-20 100m/500n 20 
JI-13 F 88 159 36 34.8 Nil 100m/150n 20 
DY-14 M 101 172 34 34.1 15 150m / 450 (17pm) 40 
AA-15 F 80 163 60 30.1 12 200m/400n 20 
AN-16 M 102 166 22 37 7 450 (12pm) 40 
NN-17 M 74 175 47 24.2 20 250 (14pm) 40 
IH-18 F 101 170 58 35 13 200m/400n 20 
JL-20 F 66 162 58 25.1 6 400m/250n 20 
TY-21 M 87 181 25 26.5 15 100m/300n 20 
m: 8:00 am, n: 20:00pm 
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Table 3.2: Demographic characteristics of patients 
Age 42.80 ± 14.62 year 
Height 174 ± 8.86 cm 
Weight 89.25 ± 18.09 kg 
BMI 29.45 ± 5.50 
5 female Sex 
  15 male 
  
  
  
  
  
  
Smoking status non-smoker 4 
1-8  Cigarette(s)/day 3 
9-15 Cigarettes/day 8 
  
  
  >15 Cigarettes/day 5 
Clozapine dosage 6.02 ± 2.30 mg/kg/day  
PPI dosage 20 or 40  
 
 
3.2. Relationship Between Norclozapine/Clozapine Ratio in Plasma and 
Clozapine Clearance 
 
Clozapine clearance was calculated from the clozapine concentration data for each 
patient in conjunction with the PKS software. Details of the validation of the PKS 
model are given in section 3.4 below. The mean values of clozapine clearances were 
found to be similar at 0.443 ± 0.228 and 0.487 ± 0.264 L/hr/kg (mean±SD) in Phase 1 
and Phase 2, respectively. Individual clozapine and norclozapine concentrations in 
plasma and the ratios at 12 hour after the first clozapine dose, and clozapine clearance 
in both phases of the study are presented in Table 3.3. 
 
The ratio of norclozapine/clozapine concentrations at the trough level (12 h) was used 
as a marker of CYP1A2 activity and ranged from 0.22 to 0.915 (mean ± SD: 0.591 ± 
0.198) in the presence of rabeprazole (phase 1) and from 0.279 to 1.267 (mean ± SD: 
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0.598 ± 0.235) in the presence of omeprazole (phase 2). Nineteen patients are 
included in these analyses because the trough level for one patient could not be 
determined in the second phase of the study. The concentrations of norclozapine in 
five patients in P1 and P2 and the concentrations of clozapine in one patient in P1 
were below the LLOQ and calculated manually. However, since the concentrations 
were close to the LLOQ small decrease in precision is expected at these levels. 
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Table 3.3: Pharmacokinetic parameters of clozapine and norclozapine in both phases of the 
study 
 
Patient Clozapine 
(ng/mL) 
P1 
nor-CLZ 
(ng/mL) 
P1 
nor-CLZ/ 
clozapine P1 
Clearance
(L/h/kg) 
P1 
Clozapine
(ng/mL) 
P2 
nor-CLZ 
(ng/mL) 
P2 
nor-CLZ/ 
clozapine P2 
Clearance
(L/h/kg) 
P2 
MN-1 241 158 0.656 0.525 350 137 0.391 0.322 
GR-2 223 134 0.601 0.327 120 103 0.858 0.774 
MS-3* 147 76 0.517 0.768 120 66 0.550 0.867 
RE-4* 482 441 0.915 0.396 311 394 1.267 0.453 
DD-5* 637 250 0.392 0.19 933 260 0.279 0.145 
TE-6  208 124 0.596 0.93 125 79 0.632 1.13 
PN-7 235 141 0.600 0.479 174 131 0.753 0.609 
GH-8 545 177 0.325 0.245 451 238 0.528 0.309 
AI-9 403 253 0.628 0.235 440 221 0.502 0.236 
FE-10 100 87 0.870 0.732 116 84 0.724 0.779 
KN-11 88 79 0.898 0.869 107 89 0.832 0.632 
DR-12 451 271 0.601 0.274 632 378 0.598 0.196 
JI-13* 382 84 0.220 0.181 318 94 0.296 0.221 
DY-14 377 106 0.281 0.309 481 185 0.385 0.273 
AA-15 213 141 0.662 0.576 185 125 0.676 0.47 
AN-16 556 269 0.484 0.213 527 195 0.370 0.188 
NN-17 152 84 0.553 0.353 108 66 0.611 0.641 
IH-18 189 155 0.820 0.521 371 170 0.458 0.417 
JL-20 466 291 0.624 0.358 321 211 0.657 0.556 
TY-21 263 168  0.382    0.515 
Mean 317.9 174.5 0.591 0.443 325.8 169.8 0.598 0.487 
± SD 164.3 94.42 0.198 0.228 219.3 97.2 0.235 0.264 
(CV%) 52 54 32 51 67 57 39 54 
Nor-CLZ: norclozapine; P1: in presence of rabeprazole; P2: in presence of omeprazole; * non-smokers 
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The ratios of plasma norclozapine/clozapine concentrations were plotted as a function 
of the calculated clozapine clearance values obtained from both phases of the study 
(Figure 3.1). An analysis using Pearson’s correlation coefficient indicated a 
statistically significant linear relationship between norclozapine/clozapine ratio and 
clearance of clozapine (Pearson r = 0.361, CI=95%, p<0.05), which suggests that 
clozapine clearance is directly related to CYP1A2 activity.  The equation of the line 
was determined by linear regression to be y = 0.31x + 0.45 (r 2= 0.130).  
 
 
Figure 3.1: Correlation between clozapine clearance and the norclozapine/clozapine ratio. 
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Number of XY Pairs 39 
Pearson r 0.361 
95% confidence interval 0.051 to 0.607 
P value (two-tailed) 0.024 
P value summary * 
Is the correlation significant? (alpha=0.05) Yes 
R squared 0.130 
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3.3. Comparison of the Effects of Omeprazole and Rabeprazole on Clozapine 
Clearance 
 
Clozapine clearance was quite variable within the patient group but intra-individual 
differences between the phases of the study were not significant. However, although 
there appeared to be a general trend toward an increase in clozapine clearance of 
approximately 10% in phase 2 of the study (Figure 3.2), the observed P value was 
0.25. Further studies are required to clarify this point. Furthermore, no significant 
difference in the AUC (0-12) in the 2 phases of the study indicates that the total 
exposure to clozapine has not differed during the 2 phases of the study (Figure 3.3). 
 
 
Figure 3.2: Comparison of the clozapine clearance in the presence of rabeprazole (P1) and in 
the presence of omeprazole (P2). 
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Paired t test  
  P value 0.249 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=1.188 df=19 
  Number of pairs 20 
 
 
 
 
 
 
 
80 
 
Figure 3.3: Comparison of the AUC (0-12) in the 2 phases of the study 
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Paired t test  
  P value 0.922 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.099;  df=19 
  Number of pairs 20 
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Supporting these observations the norclozapine/clozapine ratio at trough level was not 
different between the phases of the study. Figure 3.4 shows the distribution of the 
norclozapine/clozapine ratio in both phases of the study. 
 
 
Figure 3.4: Comparison of the norclozapine/clozapine ratio in the presence of rabeprazole 
(P1) and in presence of omeprazole (P2). 
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Paired t test  
  P value 0.834 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.213 df=18 
  Number of pairs 19 
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To further evaluate the population differences between the study phases, the study 
group was divided into smokers and non-smokers. Again, however, neither the 
clozapine clearance nor the ratio of norclozapine/clozapine differed between the study 
phases in the non-smoker group (Figure 3.5 and 3.6) and smokers (Figures 3.7 and 
3.8).  
Closer examination of the clearance values and norclozapine/clozapine ratios in the 
non-smokers (as depicted in Figure 3.5 and 3.6) suggest that both clearance and 
norclozapine/clozapine ratios were higher in the omeprazole phase in 3 of the 4 non-
smokers. However, investigation of the medical history of the only non-smokers who 
showed a decrease in both clozapine clearance and norclozapine/clozapine ratio in 
phase 2 of the study revealed no significant reason for this observation. 
 
Figure 3.5: Comparison of the clozapine clearance the in the presence of rabeprazole (P1) 
and in the presence of omeprazole (P2) in 4 non-smoker patients. Bold line indicates the 
patient who showed a decrease in clozapine clearance in the presence of omeprazole. 
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Paired t test  
  P value 0.303 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=1.240 df=3 
  Number of pairs 4 
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Figure 3.6: Comparison of the norclozapine/clozapine ratio in the presence of rabeprazole 
(P1) and in the presence of omeprazole (P2), in non-smokers. Bold line indicates the patient 
who showed a decrease in the norclozapine/Clozapine ratio in the presence of omeprazole. 
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Paired t test  
  P value 0.434 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.900 df=3 
  Number of pairs 4 
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Figure 3.7: Comparison of the clozapine clearance in the presence of rabeprazole (P1) and in 
the presence of omeprazole (P2) in smoker patients. 
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Paired t test  
  P value 0.399 
  P value summary ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.867; df=15 
  Number of pairs 16 
 
Figure 3.8: Comparison of the norclozapine/clozapine ratio in the presence of rabeprazole 
(P1) and in the presence of omeprazole (P2), in smokers. 
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Paired t test  
  P value 0.788 
  P value summary Ns 
  Are means signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  t, df t=0.274; df=14 
  Number of pairs 15 
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3.3.1. Influence of Smoking on Clozapine Concentrations 
 
One-way analysis of variance was used to determine the impact of smoking on 
clozapine plasma concentrations. Dividing patients into smoker and non-smoker 
groups showed that clozapine trough levels are significantly higher in non-smokers 
than in smokers in both phases of the study (Figure 3.9). However, the mean 
clozapine clearance and the ratio of norclozapine/clozapine plasma concentrations in 
smokers were not significantly different to those in non-smokers in both phases of 
the study. Figure 3.10 and Figure 3.11 show the comparison of the influence of 
smoking on clozapine clearance and norclozapine/clozapine ratio in both phases of 
the study. 
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Figure 3.9: Influence of smoking on clozapine plasma concentrations in both phases of the 
study. 
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One-way analysis of variance  
P value *** P<0.0001 
Are means signif. different? (P < 0.05) Yes 
Number of groups 4 
F 8.845 
R squared 0.146 
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Figure 3.10: Influence of smoking on clozapine clearance in both phases of the study. 
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Figure 3.11: Influence of smoking on norclozapine/clozapine ratio in both phases of the 
study. 
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One-way analysis of variance  
P value 0.935 
P value summary ns 
Are means signif. different? (P < 0.05) No 
Number of groups 4 
F 0.141 
R squared 0.012 
 
One-way analysis of variance  
P value 0.969 
P value summary ns 
Are means signif. different? (P < 0.05) No 
Number of groups 4 
F 0.083 
R squared 0.007 
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3.4. Impact of other covariates on clozapine clearance 
 
3.4.1. Age 
 
The relationship between age and clozapine clearance is shown in Figure 3.12. 
Significant relationships were not apparent in either phase of the study.  
 
 
Figure 3.12: The influence of age on clozapine clearance 
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 P1 P2 
Number of XY Pairs 20 20 
Pearson r 0.145 0.366 
95% confidence interval -0.317 to 0.553 -0.092 to 0.696 
P value (two-tailed) 0.540 0.113 
P value summary ns ns 
Is the correlation significant? (alpha=0.05) No No 
R squared 0.021 0.134 
 
 
 
 
 
 
 
 
89 
 
3.4.2. Gender 
 
The Mann-Whitney test was applied to compare clozapine clearance in male and 
female patients but the influence of gender was not significant. It is suggested from 
Figure 3.13 that the mean value of clozapine clearance may have been lower in males 
than in females. However, the small number of the subjects recruited in this study and 
the large inter-individual variation in clearance resulted in a non significant 
relationship. Figure 3.13 indicates the relationship between gender and clozapine 
clearance. 
 
Figure 3.13: The effect of gender on clozapine clearance 
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Mann Whitney test  
  P value 0.960 
  Exact or approximate P value? Gaussian Approximation 
  P value summary ns 
  Are medians signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  Mann-Whitney U 138.0 
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3.4.3. Weight 
 
No correlation was found between patients weight (kg) and clozapine clearance (L/hr) 
in either phase of the study. Figure 3.14 shows the relationship between weight and 
clozapine clearance. 
 
Figure 3.14: The relationship between weight and clozapine clearance 
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Number of XY Pairs 20 20 
Pearson r 0.348 -0.037 
  95% confidence interval -0.111 to 0.685 -0.472 to 0.412 
P value (two-tailed) 0.132 0.877 
  P value summary ns ns 
  Is the correlation significant? (alpha=0.05) No No 
  R squared 0.121 0.001 
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3.4.4. Body Mass Index (BMI) 
 
The relationship between BMI and clozapine clearance was investigated to test further 
whether these may be a relationship between patient weight and clozapine clearance. 
Significant negative correlation was observed between BMI and clozapine clearance 
in phase 2 (Pearson r = -0.561, r 2 = 0.314, p<0.05), but not in phase 1. The results are 
shown in Figure 3.15. 
 
Figure 3.15: Correlation between clozapine clearance and Body Mass Index (BMI). 
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 P1 P2 
Number of XY Pairs 20 20 
Pearson r -0.202 -0.561 
  95% confidence interval -0.592 to 0.264 -0.804 to -0.157 
P value (two-tailed) 0.393 0.010 
  P value summary ns * 
  Is the correlation significant? (alpha=0.05) No Yes 
  R squared 0.041 0.314 
 
To further evaluate the relationship between clozapine clearance and BMI, the 
patients in phase 2 were separated into two groups based on BMI>25 (n=15) and 
BMI<25 (n=5), since 25 is considered borderline obesity. The mean value of 
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clozapine clearance was significantly greater in patients with BMI<25 than in patients 
with BMI>25 (Figure 3.16). When the same approach was taken for data in phase 1, 
the mean value of clozapine clearance was approximately 13.8% higher in patients 
with BMI<25. However, this did not attain statistical significance (Figure 3.17).   
 
Figure 3.16: Comparison of clozapine clearance in two groups with BMI>25 and BMI<25 in 
Phase 2. 
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  P value 0.036 
  Exact or approximate P value? Gaussian Approximation 
  P value summary * 
  Are medians signif. different? (P < 0.05) Yes 
  One- or two-tailed P value? Two-tailed 
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Figure 3.17: Comparison of clozapine clearance in two groups with BMI>25 and BMI<25 in 
Phase 1. 
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  P value 0.431 
  Exact or approximate P value? Gaussian Approximation 
  P value summary ns 
  Are medians signif. different? (P < 0.05) No 
  One- or two-tailed P value? Two-tailed 
  Mann-Whitney U 26.00 
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3.5. Evaluation of the Model Obtained with the Abbottbase Bayesian PKS 
Program 
 
The accuracy and precision of the model that was developed using the Abbottbase 
Bayesian approach were evaluated using the internal and the external data.  
 
3.5.1. Internal Evaluation of PKS: 
 
Details of the performance evaluation of Bayesian Abbottbase PKS modeling of the 
internal data are presented in Table 3.4. The results indicated strong correlation 
between the Bayesian predicted clozapine concentrations and actual clozapine 
concentrations (Pearson r = 0.971, 95% CI, P<0.0001, r2=0.943) for all sampling time 
points (Figure 3.18) and for each of the individual sampling time points at 0.5, 1, 2 
and 12 h in both phases of the study (Table 3.4). Residual values indicated that the 
majority of the predicted clozapine concentrations are distributed around the identity 
line (Figure 3.18.b). 
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Figure 3.18: Graphical goodness-of-fit display for the Bayesian Abbottbase Pharmacokinetic 
System. (a) Correlation between the actual and Bayesian predicted clozapine concentrations 
(ng/mL) for all time points (0.5, 1, 2, 12 hr) in both phases of the study. (b) Plot of residuals 
of response versus predicted clozapine concentrations. (c) Difference between mean of the 
predicted and actual clozapine concentrations.  
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Pearson r 0.971 
95% confidence interval 0.961 to 0.979 
P value (two-tailed) P<0.0001 
P value summary *** 
Is the correlation significant? (alpha=0.05) Yes 
R squared 0.943 
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Table 3.4: Comparison of observed and Bayesian predicted clozapine plasma concentrations  
at single sampling time point at 0.5, 1, 2, and 12 hr after the first dose of clozapine and all 
sampling time points in both phases of the study. 
 
Sampling 
time (h) 
r2 
 
RMSE 
(mg/mL) 
RMSE
% 
ME 
(mg/mL) 
ME 
% 
0.5 0.921 0.054 13.5 -0.027 -6.8 
1 0.929 0.053 13.2 -0.017 -4.25 
2 0.927 0.061 15.2 -0.004 -1 
12 0.969 0.038 9.5 -0.013 -3.27 
All time points 0.943 1.65 0.1 -0.0071 -0.44 
 
RMSE: Root Mean Square Error (precision).  
ME: Mean Predicted Error (bias) 
r2 :All coefficient of determination (r2) were statistically significant (p < 0.0001) 
Note units are mg/mL instead of ng/mL to improve clarity. 
 
 
 
 
 
  Mean ± SEM of column A 375.9 ± 17.23  
  Mean ± SEM of column B 382.9 ± 16.30  
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The AUC0-12 of clozapine was calculated by the log trapezoidal method, using 
predicted and actual clozapine concentrations.  The correlation between predicted and 
actual  
AUC0-12 is shown in Figure 3.19. The results suggested a significant correlation 
between predicted and actual AUC0-12. (95% CI, α=0.05, p<0.0001, r2=0.997).   
 
 
Figure 3.19: (a) Comparison of predicted and observed AUC0-12 for clozapine at 0.5, 1, 2 and 
12 h after clozapine in both phases of the study. (b) Plot of residuals versus predicted   AUC0-
12. 
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The overall results suggest that the Abbottbase prediction tended to overestimate the 
clozapine concentration with a precision (RMSE) ≤0.054, 0.053, 0.061and 0.038 
mg/mL for samples collected at 0.5, 1, 2 and 12 h, respectively. The strong correlation 
between predicted and actual clozapine concentrations and AUC0-12 indicate that the 
prediction performance of Bayesian Abbottbase Pharmacokinetic System (PKS) for 
clozapine clearance is good. 
 
 
3.5.2. External Evaluation of PKS 
 
External model evaluation was determined by plotting the actual and predicted 
concentration-time curve of trough concentrations of plasma clozapine with 38 
subjects derived from another study (obtained by personal communication with 
researchers). The results again showed a strong correlation between the predicted and 
actual concentration of clozapine concentrations (Pearson r = 0.998, 95% CI, α=0.05, 
p<0.0001, r2=0.996, Figure 3.20). The bias was low (about 0.08%) and the 
Abbottbase predictions again tended to overestimate the clozapine concentration with 
≤3.5% or 1.344 mg/mL at trough level (Table 3.5).  
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Figure 3.20: Comparison of predicted and observed clozapine concentrations at trough levels 
for a 38 patients external data set  
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Number of XY Pairs 38 
Pearson r 0.998 
95% confidence interval 0.996 to 0.999 
P value (two-tailed) P<0.0001 
P value summary *** 
Is the correlation significant? (alpha=0.05) Yes 
R squared 0.996 
 
 
 
 
Table 3.5: Performance evaluation of the Bayesian Abbottbase Pharmacokinetic System 
(PKS) for the external data 
 
Sampling 
time (h) 
r2 
 
ME 
(mg/mL) 
ME% 
 
RMSE 
(mg/mL) 
RMSE% 
 
 
12 0.996 0.030 0.08 1.344 3.50% 
 
RMSE: Root Mean Square Error (precision). 
ME: Mean Predicted Error (bias) 
r2 : All coefficient of determination (r2) were statistically significant (p < 0.0001) 
Note units are mg/mL instead of ng/mL to improve clarity. 
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CHAPTER FOUR:  
DISCUSSION 
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4. Discussion 
 
CYP1A2 contributes to the disposition of many drugs including the antipsychotics, 
clozapine and olanzapine, and methylxanthines such as caffeine and theophyline. It 
has been reported that, apart from cigarette smoke, certain diets and concurrent 
medications may also alter CYP1A2 activity. For instance, fluvoxamine, 
fluoroquinolones and oral contraceptives inhibit CYP1A2 activity whereas 
barbiturates increase enzyme activity (www.medicine.iupui.edu/flockhart/table.htm). 
A number of allelic variations of CYP1A2 have been described, which may contribute 
to inter-individual variation in CYP1A2 activity (Sachse et al 1999, Han et al 2001). It 
is important to note that, in contrast to genetic factors, the influence of environmental 
factors and other medications on enzyme activity are transient (Faber et al 2005). 
Although, there may up to 60 fold variations in expression of the CYP1A2 gene, 
recent study has shown that no SNPs or haplotypes of the CYP gene have been 
significantly associated with CYP1A2 metabolic phenotype (Jiang et al 2006). 
Therefore, rather than genotyping, phenotyping tests might be useful for 
determination of CYP1A2 activity before and during drug therapy, particularly for 
those drugs with a narrow therapeutic index, such as clozapine. This information 
could assist medication efficacy assessment, possible interactions, avoid toxicity or 
side effects and nonresponse.  Caffeine, a drug which is highly dependent on 
CYP1A2 for its metabolism, has been used as an in vivo probe for CYP1A2 
phenotype. In this method CYP1A2 activity is assessed by measuring the 
paraxanthine/caffeine ratio in urine (Fuhr & Rost 1994).  
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It has been shown that clozapine clearance also correlates with CYP1A2 activity 
(Doude van Troostwijk et a1 2003b). It is suggested that CYP1A2 activity is 
responsible for about 70% of the variation in oral clearance of clozapine (Bertilsson et 
al 1994). Indeed apart from the caffeine clearance test, some studies have shown that 
the ratio of norclozapine/clozapine correlates with CYP1A2 activity (Dailly et al 
2002; Carrillo et al 1998; Bertilsson et al 1994). 
 
 The results show that there is a direct relation between clozapine clearance and the 
ratio of trough concentrations of norclozapine/clozapine in plasma (Pearson r = 
0.3607; p<0.05), which supports the assertion that clozapine clearance is directly 
related to CYP1A2 activity. Since some side effects of clozapine such as seizures, 
sedation and hypotension seem to appear at high plasma concentrations that exceed 
1000 ng/mL (Chetty and Murray 2007) regular monitoring of clozapine plasma 
concentrations is recommended.  Therefore, the ratio of norclozapine/clozapine could 
be a convenient substitute for the caffeine test, which can be performed in a context of 
therapeutic drug monitoring in patients who are taking clozapine. Furthermore, this 
test might be of clinical value in identification of an individual’s metabolic capacity to 
avoid clozapine toxicity or adverse effects. Another advantage is that administration 
of caffeine would be avoided which could decrease the likelihood of impairment of 
clozapine administration. 
 
Phenotyping tests may also assist the investigation the impact of drug exposure on the 
activity of particular CYPs, which could be used to detect drug-drug interactions 
caused by CYP induction or inhibition. Since omeprazole is amongst the CYP1A2 
inducers, it might be expected that co-medication with clozapine and omeprazole 
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could influence clozapine elimination as a consequence of induction of CYP1A2 
activity.  
 
The concomitant use of clozapine and other agents for treatment of gastrointestinal 
disorders caused by clozapine therapy happens frequently. Omeprazole is a widely 
used PPI for the treatment of acid related disease. It has been reported that 
omeprazole therapy in two patients with schizophrenia decreased plasma clozapine 
concentrations, possibly as a consequence of CYP1A2 induction (Frick et al 2003). 
Replacement of omeprazole with pantoprazole, an alternative PPI agent with a weaker 
CYP1A2 induction capacity, resulted in an increase in plasma clozapine 
concentrations in patients (Mookhoek & Loonen 2004). 
 
In vitro studies have indicated that the expression of CYP1A1 and 1A2 mRNAs 
increases in cells that have been treated with omeprazole (Shin et al 1999; Quattrochi 
& Tukey 1993; Curi-Pedrosa et al 1993). An in vitro comparison study in HepG2 
cells showed that omeprazole and lansoprazole were more potent inducers of both 
CYP1A1 and 1A2 than rabeprazole. Moreover, this study showed that another PPI – 
pantoprazole – did not induce CYP1A2 (Krusekopf et al 2003).  
 
We compared the CYP1A2 activity in the presence of both rabeprazole and 
omeprazole, using the ratio of norclozapine/clozapine as a probe for CYP1A2 
activity, in patients with schizophrenia. There was no difference in the 
norclozapine/clozapine ratio after replacing concurrent rabeprazole with omeprazole. 
In support of this result, clozapine clearance was not different in patients who 
received either rabeprazole or omeprazole.  
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Some studies have indicated that the induction of CYP1A2 by omeprazole is dose 
dependent and that omeprazole is not a CYP1A2 inducer at conventional therapeutic 
doses (20 mg/day) (Andersson et al 1998; Rizzo et al 1996; Sinues et al 2004). Rost et 
al showed that at the higher therapeutic dose level of 40 mg/day, omeprazole induces 
CYP1A2 activity in subjects who are PMs for CYP2C19 but not EMs (Rost et al 
1994). In contrast, another study on 14 healthy subjects compared the induction of 
omeprazole (20 mg), lansoprazole (30 mg) and pantoprazole (40 mg). Despite the 
increased AUC with three PPIs in PMs for CYP2C19, there was no evidence of 
CYP1A2 induction in patients of either genotype (Andersson et al 1998).  
 
Another study reported that high dose omeprazole (40 and 60 mg/day, 
respectively)   in two schizoaffective patients who were also smokers decreased 
plasma clozapine concentrations by 41.9% and 44.7%, respectively (Frick et al 
2003). It was suggested that the induction of CYP1A2 by omeprazole may have 
led to the decrease in clozapine concentrations.  
 
In our study, the daily dose of rabeprazole and omeprazole remained constant in 
both phases of the study. Sixteen of the patients were taking PPIs 20 mg/day, 
while the remainder received 40 mg daily.  
The use of low therapeutic doses of the PPIs omeprazole and rabeprazole (20 and 
40 mg/day) in the present study may explain the lack of induction of CYP1A2 
activity. Clozapine clearance did not differ between either phase of the study.  
Although, the present study did not evaluate CYP2C19 phenotype among the 
subjects, previous studies have shown that only 2 to 5% of Caucasians are PMs 
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for CYP2C19 (Rettie et al 2000); 90% of the recruited patients were Caucasian. 
Therefore, the non significant trend toward higher clozapine clearance in 
presence of omeprazole might have been affected by the likely low incidence of 
PMs for CYP2C19. 
 
Mookhoek and Loonen reported that replacement of omeprazole with 
pantoprazole in 10 smokers led to a decrease in the mean serum clozapine 
concentration by 41 µg/L. However, in 3 non-smoking patients the clozapine 
concentrations increased by 134 µg/L. It was suggested that replacement of 
omeprazole, as established CYP1A2 inducer, by the much less potent 
pantoprazole may have caused the rise in clozapine concentrations in 
nonsmokers. In contrast, the remaining smoking subjects may have been 
maximally induced in terms of CYP1A2 activity (Mookhoek & Loonen 2003).  
 
A comparison of smokers and non smokers in our study indicates that the 
smokers have lower mean plasma clozapine concentrations than non smokers 
(336.3 ng/mL vs 563.1 ng/mL, P<0.0001, in the presence of rabeprazole and 336 
vs 541.9, P<0.0001, in the presence of omeprazole). The slightly higher 
clozapine clearance in smokers compared to non smokers did not reach statistical 
significance. Although the phenotyping marker (norclozapine/clozapine in 
plasma) suggested that CYP1A2 activity was greater in smokers, the difference 
was not also significant. The small number of non-smokers in this study may 
help to explain the non significant results in these analyses, although this is 
likely to remain a problem in studies of this type in patients with schizophrenia.  
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Despite the efficacy of clozapine in treatment of refractory schizophrenia, it has 
been reported that clozapine therapy is an additional risk factor for metabolic 
disorders (Lamberti et al 2006). Weight gain, elevation of liver enzymes, 
diabetes mellitus, fatty liver and lipid abnormalities such as increased total 
cholesterol levels and hypertriglyceridemia are among the side effects of 
clozapine (Rettenbacher et al 2006; Lamberti et al 2006; Henderson et al 2000). 
Moreover, weight gain may also be associated with elevation of liver enzymes in 
patients with schizophrenia treated with second generation antipsycotics 
(Rettenbacher et al 2006). For instance, Gaertner et al reported an elevation of at 
least one of the LFTs, usually aspartate transaminase (AST) or alanine transaminase 
(ALT), in 49% of 330 clozapine treated patients. This rate was 61% in patients who 
received clozapine monotherapy (Gaertner et al 1989).  
 
Our results also suggested such an association between clozapine therapy and 
elevation of liver enzymes. Almost 60% of patients in our study showed an increase 
in at least one of the liver test functions, usually ALT or GGT (γ-glutamyl 
Transpeptidase).  
The previous results do not support a differential induction effect of omeprazole or 
rabeprazole on CYP1A2 activity at the conventional dosages that were used in this 
study. Instead, a significant negative correlation between the BMI and clozapine 
clearance in phase 2 (in presence of omeprazole) may be informative. Inhibitory 
effects of lipids on clozapine metabolism are consistent with reports that clozapine 
clearance is significantly lower in obese patients with BMI>25.  
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Subsequent studies have suggested that BMI is a new source of CYP1A2 variability 
(Tantcheva-poor et al 1999; Hong et al 2004). Tantcheva-poor investigated the 
influence of covariates such as: age, gender, oral contraceptives, body height, body 
weight, BMI, number of cigarettes smoked, caffeine consumption and country of 
residence on CYP1A2 activity in 863 healthy Caucasians using caffeine clearance 
data derived from saliva. A significant relationship between BMI and caffeine 
clearance was reported. The estimated change relative to the defined basal caffeine 
clearance was 0.99 fold kg/m2 in this study. The author pointed to the 1.16 fold 
higher caffeine clearance in an individual subject with a BMI 20 (kg/m2) compared 
with another subject with a BMI 35 (kg/m2) (Tantcheva-poor et al 1999).   
 
Moreover, overall obesity which is indicated by BMI has been shown to be strongly 
related to increased levels of serum lipid and lipoprotein (Nakanishi et al 1999) and is 
also associated with the development of hepatic steatosis (Zhang et al 2007). 
 
A recent study investigated the influence of fatty liver (steatosis) on CYP activity. It 
was shown that the expression and activity of several CYPs, including CYP1A2, 2A6, 
2B6, 2C9, 2D6, 2E1 and 3A4 were reduced by 45% to 65% in hepatocytes that were 
treated with 1mM free fatty acids for 14h (Donato et al 2006). 
 
Consistent with Donato et al, another recent in vitro study has shown a significant 
decrease in CYP1A2, 2C11, 2E1, and 3A activity in steatotic liver in rat (Zhang et al 
2007). The results of this study also showed that the formation of norclozapine 
decreased significantly in steatotic liver, even though the formation of clozapine-N-
oxide was unchanged. Interestingly, the fraction unbound of clozapine was 
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significantly lower in microsomes from steatotic liver compared with the control liver 
(Zhang et al 2007). 
 
Thus, there are three potential explanations that may account for the negative 
correlation between clozapine clearance and BMI.  
First, BMI could be a covariate that could reduce CYP1A2 activity, resulting in a 
lower clearance of clozapine in obese patients.  
Secondly, fatty liver resulting from clozapine-induced metabolic syndrome could 
decrease CYP1A2 activity in obese patients. 
Thirdly, the unbound fraction of clozapine in plasma of obese individuals could 
impair clearance. Since clozapine has a low hepatic extraction ratio (0.17±0.11; 
Jann et al 1993), its clearance depends on protein binding. Therefore, the 
increased levels of serum lipoproteins may decrease the unbound fraction of clozapine 
in plasma and decrease clozapine clearance in obese patients according to the 
following expression: 
CLh=Fu CLint 
Where, CLh is clozapine hepatic clearance, Fu is unbound fraction in plasma and 
CLint is intrinsic enzyme activity.   
 
Considered together, a decrease in clozapine metabolism may occur during weight 
gain in obese subjects. Lipid that accumulates in liver in patients with metabolic 
syndrome and steatosis may down regulate CYP1A2 expression and impair clozapine 
disposition by the mechanisms suggested above. 
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The influence of age and gender on clozapine metabolism is inconsistent. While 
some studies have shown the higher plasma clozapine concentrations in older 
patients (Haring et al 1989), Perry et al did not find a significant relationship 
between age and clozapine concentrations (Perry et al 1998).  
 The small number of patients recruited in many of these studies could explain 
the inconsistency of findings (Rostami-Hodjegan et al 2004). Rostami-Hodjegan et 
al reported that the higher plasma clozapine concentrations in females may be due to a 
higher body fat composition and therefore higher volume of distribution. Also, the 
lower CYP1A2 activity in females could explain the decrease in clozapine clearance 
that was observed (Rostami-Hodjegan et al 2004).  
 
The current results did not find any statistically significant correlations between 
age and gender with clozapine clearance, which could be due in part to the small 
number of recruited patients in the study. 
In conclusion, the present results are consistent with suggestions that the ratio of 
trough serum norclozapine/clozapine concentrations could be a convenient marker 
that reflects CYP1A2 activity in patients with schizophrenia who are receiving 
clozapine therapy.  
The present study also suggests that the selection of either rabeprazole or omeprazole 
should not affect serum clozapine concentrations when used at common therapeutic 
dosage (20 to 40 mg/day). Because other studies have suggested that omeprazole is a 
CYP1A2 inducer at high dose, its effect now appears to be dose dependent.  
Consistent with other studies, the clozapine concentrations were lower in smokers 
than in non smokers in both phases of the study.  
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For the first time we have found that a BMI higher than 25 may be associated with 
decreased clozapine clearance. It seems that there is a negative correlation between 
BMI and clozapine clearance which could be as a result of CYP1A2 down-regulation 
due to weight gain, lipid abnormalities and steatosis. The increased level of plasma 
lipoproteins in obese patients may decrease the unbound fraction of clozapine, reduce 
the availability of the drug for oxidation by CYP1A2 and decrease clozapine 
clearance.  This issue is important for some drugs such as clozapine, which may affect 
clozapine efficacy and toxicity. 
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Appendix I  
 
Patients’ Co-medications 
Patients 
Code 
                                      Co-medications 
MN-1 Meloxicam, Quetiapine, Trihexiphenidyl 
GR-2 Atorvastatin, Na valproate, Lactulose, Sertraline, Folic acid, Thiamine 
MS-3 Quilonium (Lithium) 
RE-4 Fybrogel 
DD-5 Na valproate, Haloperidol, Atorvastatin 
TE-6 Finastride, Amitriptyline, Coloxyl-Senna 
PN-7 Na valproate, Sertraline, Thyroxin, Coloxyl-Senna, Lactulose, Metamucil 
GH-8 Na valproate, Benztropine, Haloperidol, Duphalac, Coloxyl-Senna  
AI-9 Sertraline, Lipitor, Coloxyl-Senna, Fybrogel 
FE-10 Topiramate 
KN-11 Na valproate 
DR-12 Sertraline 
JI-13 Sertraline, Na valproate, Atorvastatin, Microgynon, Insulin mixtard, 
Metformin 
DY-14 Na valproate, Venlafaxine, Lactulose, Fybrogel 
AA-15 Sertraline,  Mixtard insulin, Lipitor, Coloxyl-Senna 
AN-16 Sertraline, Lithium Retard, Nicotine gum 
NN-17 Venlafaxine, Cephalexine, Lipitor, Thiamine 
IH-18 Metformin, Lithium, Fybrogel 
JL-20 Thyroxin, Na valproate, Folic acid, Coloxyl-Senna, Tamoxifen, Sertraline, 
Paracetamol 
TY-21 None 
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Appendix II 
 
Macquarie Hospital 
Wicks Road, North Ryde 2113 
PO Box 169, North Ryde NSW 1670 
Telephone (02) 9888 1222  Facsimile (02) 9887 5684 
 
_____________________________________________________________________________________________ 
 
 
 
Participant Information Sheet  
Site: Macquarie Hospital 
 
1.   Study Title: 
 A comparison of the effect of omeprazole and rabeprazole on clozapine serum 
concentrations. 
 
2.   Your consent to participate: 
We invite you to take part in this research project which will be conducted by 
Naghmeh Jabarizadekivi as part of a masters degree. Dr Glenys Dore and Dr. Mano 
Chetty will oversee the project.  
 
This Participant Information Sheet contains detailed information about the research 
project. Its purpose is to explain to you as openly and clearly as possible all the 
procedures involved in this project before you decide whether or not to take part in it. 
 
Please read this participant information sheet carefully. Feel free to ask questions 
about any information in the document. You may also wish to discuss the project with 
a relative or friend. Feel free to do this. 
 
Once you understand what the project is about and if you agree to take part in it, you 
will be asked to sign the Consent Form. By signing the Consent Form, you indicate 
that you understand the information and that you give your consent to participate in 
the research project. 
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You will be given a copy of the Participant Information Sheet and Consent Form to 
keep as a record. 
 
 
 
3.   Purpose of the study:  
You are already on the medications called rabeprazole and clozapine or clozapine alone. 
Rabeprazole treats the symptoms of heartburn, which can occur when you are on clozapine. 
Another similar drug, called omeprazole, is also used to treat symptoms of heartburn. It is 
reported that using both omeprazole and clozapine may reduce the clozapine level due to the 
increase the break down of clozapine by the enzymes in the liver. Rabeprazole is a new drug 
that belongs to the same family as omeprazole.  
In this study we would like to see whether rabeprazole has similar affect on clozapine level. 
In addition we would like to see how rabeprazole affects the liver enzymes that metabolise 
clozapine. All those changes may affect the dose of clozapine that has to be taken when these 
drugs are given together. 
This study would help the clinicians in choosing the best dose for the patients. 
 
4.   Why has the participant been chosen? 
You are taking clozapine or clozapine and rabeprazole as a part of your routine medication. 
You are invited to this study because we want to determine how omeprazole and rabeprazole 
affect the clozapine clearance. This may result in better dosing with clozapine. A total 30 
patients will participate in this study.   
 
5.   Participation: 
Participation in any research project is voluntary. If you do not wish to take part you 
are not obliged to. If you decide to take part or not to take part, or to take part and 
then withdraw, it will not affect your routine treatment, your relationship with those 
treating you or your relationship with the hospital.  
The therapy for your illness is unaffected by your decision of whether or not to 
participate in this project. Treatment and clinical management of your condition will 
be the same regardless of your participation in the research project. 
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In the unlikely event that you suffer an injury as a result of participating in this 
research project, hospital care and treatment will be provided by the public health 
services at no extra cost to you. 
 
 
6.   Reimbursement for your participation: 
You will be paid $40 for your participation in this trial. If you are taking clozapine without 
rabeprazole or omeprazole, you will be given $15 because you will be participating for a 
shorter period and a fewer number of blood samples will be taken. 
 
7.   Procedure: 
A total of 30 patients will participate in this study. 
 
You will already be taking clozapine and rabeprazole as a part of your routine 
medication. During the first part of this study, there is no change in your medication. 
The dosage of clozapine and rabeprazole you need will be decided by your doctor. 
The plasma clozapine will be measured after at least two weeks of treatment with 
these both of these medications. In addition to your usual blood sample that is taken 
about 12 hours after your medication, 3 further blood samples (10 ml each) will be 
taken at 30min, 1 hr and 2 hrs after you have taken clozapine. The blood sample will 
be taken by the clinical nurse specialist. Rabeprazole will then be switched to 
omeprazole and plasma concentration of clozapine will be measured after at least one 
month of taking medication, at the same sampling intervals as above.  
 
On the first day after rabeprazole is changed to omeprazole, two blood samples will 
be taken. These blood samples will be used to analyse the activity of specific liver 
enzymes.   
 
If you are taking clozapine without rabeprazole or omeprazole, in addition to your usual blood 
sample that is taken about 12 hours after your medication, 3 further blood samples (10 ml 
each) will be taken at 30min, 1 hr and 2 hrs after you have taken clozapine. This will be done 
once only. 
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8.   The participant's responsibilities: 
It is important to tell your doctor and the research staff about any treatments or 
medications you may be taking, including non-prescription medications, vitamins or 
herbal remedies and any changes to these during your participation in the study.  
 
9.   The side effects and possible disadvantages of taking part: 
Omeprazole and rabeprazole work in the same way and they are well-tolerated drugs. 
Therefore the only one change from rabeprazole to omeprazole will not create serious 
side effects or interfere with your regular treatment.  
Common side effects of omeprazole: 
Headache, abdominal pain, nausea, vomiting, constipation, diarrhoea, flatulence. 
Uncommon side effects of omeprazole: 
Rash, dizziness, vertigo, increased liver enzymes, malaise. 
Rare side effects of omeprazole: 
Hypersensitivity reactions, e.g. fever, bronchospasm. 
 
Some discomfort may be experienced when blood sample are taken. 
 
10.   Terminate the involvement: 
If you wish to withdraw from the study at any time, you can do so by contacting Dr. 
Glenys Dore and signing the withdrawal form. Withdrawal from the study will not 
affect your treatment or care. 
Before you make your decision, a member of the research team will be available so 
that you can ask any questions you have about the research project. You can ask for 
any information you want. Sign the consent form only after you have had a chance to 
ask your questions and have received satisfactory answers. 
 
11.   Privacy, confidentiality and disclosure of information:  
Blood samples will be potentially identifiable with a code. The investigators will have 
access to the code that could identify individual samples. Both blood samples and 
information will be collected from the Macquarie Hospital and will be transferred to 
the Faculty of Pharmacy, Sydney University by the researcher (Naghmeh 
Jabarizadekivi). The original information will be held in a locked cupboard in the 
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Faculty of Pharmacy and electronic information will be held in password-protected 
files on the personal computer of the researcher (Naghmeh Jabarizadekivi) in the 
Faculty of Pharmacy, Sydney University. Data will be stored in files for 7 years after 
completion of the research. Thereafter all the data will be shredded or deleted. In any 
presentation of the findings of this study, identification of participants will not be 
possible. 
 
We will not establish a human tissue bank using the blood samples obtained in this 
project. The samples will only be in the present research project and not in any other 
studies or for any commercial purpose. 
 
This study does not have the capacity to provide information about an individual's 
future health or risk of having children with a genetic disorder, or information that 
may be relevant to the health of family members who are not the part of the study.  
 
There is no potential for this research to detect or generate information of social 
significance (e.g. non-paternity or non-maternity) or information that may influence 
access to insurance/employment. There is no potential for this research to detect or 
generate information concerning genetic diseases. 
 
Any information obtained in connection with this research project that can identify 
you will remain confidential and will only be used for the purpose of this research 
project and no other projects. 
 
12.   Results of project: 
The investigators at Macquarie Hospital can provide you with the overall results of 
the study if you are interested. 
 
13.   Investigators, organizing and funding: 
This project will be conducted mainly by investigators, Dr Mano Chetty and 
Naghmeh Jabarizadekivi from the Faculty of Pharmacy, University of Sydney and Dr 
Glenys Dore from Macquarie Hospital. Funding for this study was obtained from the 
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University of Sydney. Accordingly, we seek your consent for these blood samples to 
be measured in the Faculty of Pharmacy, Sydney university. 
 
14.  Further information or any other problems: 
If you require further information or you have any problems concerning this project 
(for example, any side effects), you can contact Dr Glenys Dore at 98881222 or by 
dialling -9- in the hospital and asking to page her.  
 
15.   Other issues: 
If you have any complaint about any aspect of the project, the way is being conducted 
or any question about your rights as a research participant, then you may contact 
Michael Herman 
Position Held: Psychologist 
Telephone: 98881222 or -9- in the hospital 
You need to tell Michael Herman the name of one of the researchers given in section 
12 above. 
 
16.   Ethical Guidelines: 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999). This statement has been 
developed to protect the interests of people who agree to participate in human 
research studies. 
The ethical aspects of this research project have been approved by the Northern 
Sydney Health Human Research Ethics Committee. 
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Appendix III 
 
 
Macquarie Hospital 
Wicks Road, North Ryde 2113 
PO Box 169, North Ryde NSW 1670 
Telephone (02) 9888 1222  Facsimile (02) 9887 5684 
 
_____________________________________________________________________________________________ 
 
 
 
Consent form to Participate in a research Project 
 
I,  
                    
 
of  
       
 
 
have been invited to participate in a research project entitled " A comparison of the 
effect of the omeprazole and rabeprazole on clozapine serum concentrations". 
 
In relation to this project I have read the Participant Information Sheet and have been 
informed of the following points: 
 
1.      Approval has been given by the Human Research Ethics Committee (HREC) of 
Northern Sydney Central Coast Health. 
 
 
2.       The aim of the project is to investigate whether rabeprazole has a similar     
effect on clozapine clearance as omeprazole and to determine the activity of some 
specific liver enzymes in presence of rabeprazole and omeprazole. 
 
Medications like omeprazole or rabeprazole are frequently used in the treatment 
of heartburn symptoms due to clozapine. 
 
During this research project medication will be changed from rabeprazole to 
omeprazole. 
 
3.        The results obtained from the study may or may not be of direct benefit to my 
medical management. 
 
4.     The procedure will involve giving 3 additional blood samples (10ml at 30mins, 
1hr, 2hrs) firstly after taking the rabeprazole-clozapine combination and secondly 
(name of participant)
      (street)                                (suburb/town)                             (state & postcode)
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after changing to the omeprazole-clozapine combination. In addition 2 blood samples 
will be taken on the first day after change over to omeprazole.  
 
If I am taking clozapine without rabeprazole or omeprazole, only 3 additional samples 
(10ml at 30mins, 1hr, 2hrs) will be taken from me. 
 
5.        Omeprazole is well-tolerated drug and most adverse reactions are mild and 
transient. However, most of these side effects are similar to rabeprazole. Common 
side effects of omeprazole are headache, abdominal pain, nausea, vomiting, 
constipation, diarrhoea, flatulence. Uncommon side effects of omeprazole are rash, 
dizziness, vertigo, malaise, increased liver enzymes. Hypersensitivity is one of the 
rare reactions of omeprazole, such as fever and bronchospasm. 
 
 
6.        My involvement in this project may be terminated if any of the following 
circumstances develop: 
a. serious side effects 
b. poor response to the drug combination 
c. I decide to withdraw my consent 
d. at the discretion of the psychiatrist treating me 
 
7.        Should I develop a problem which I suspect may have resulted from my 
involvement in the project, I am aware that I may contact Dr Glenys Dore 
On: 
Macquarie Hospital 
Telephone Number: 02- 98881222 
 
 
Date:  Witness: 
                                                                                                     (Please print name) 
 
Signature: Signature:  
                   (of participant/volunteer) (of witness) 
 
 
 8.       Should I have any problems or queries about the way in which the study     was 
conducted,                 and I do not feel comfortable contacting the research staff, I am 
aware that I may contact the Consumer Consultant who is an independent person 
within the Hospital on 98881222. 
 
9.       I can refuse to take part in this project or withdraw from it at any time without 
affecting my medical care. 
 
10.     I understand that take out the participating in this research may or may not 
benefit my medical treatment directly however my participating may assist in the 
development of treatments and/or procedures for the future. 
 
11.     Participation in this project will not result in any extra medical and hospital 
costs to me. I will receive $40 as reimbursement payment for my time and the blood 
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samples associated with my involvement in this study. If I am taking clozapine 
without rabeprazole or omeprazole, I will be given $15 because I will be participating 
for a shorter period and a fewer number of blood samples will be taken. 
 
12.     I understand that my research records will be stored in a locked cupboard at the 
University of Sydney. Electronic information will be held on password-protected files 
on personal computer in the laboratory of the Faculty of Pharmacy, Sydney 
University. The research team, authorized personnel, and regulatory entities may have 
access to my study records to protect my safety and welfare. 
 
 
13.     I understand that my information will be identified by a numerical random code 
together with the first letter of my first name and the last letter of my last name. This 
information is potentially identifiable but all precautions will be taken by the clinical 
staff to ensure the information will be kept confidential. 
 
14.     If the results of my tests or information regarding my medical history are 
published, my identity will not be revealed. 
 
15.     While participating in this study, I should not take part in any other research 
project without approval from all of the investigators. This is to protect myself from 
possible injury arising from such things as extra blood drawing, extra x-ray, 
interaction of research drugs, or similar hazards. 
 
16.     During the course of this study, I will be informed of any significant new 
findings (either good or bad) such as changes in the risks or benefits resulting from 
participation in the research or new alternatives to participation that might cause me 
to change my mind about participating. If such new information is provided to me, my 
consent to participate will be re-obtained. 
 
17.     In giving my consent, I acknowledge that the Government Health Department 
Officials, and the personnel directly involved in the study, may examine my medical 
records only as they relate to this project. 
 
18.     I declare that I am over the age of 18 years. 
 
After considering all these points, I accept the invitation to participate in this project. 
 
I am aware that I will be given a copy of the Participant Information Sheet and 
Consent Form. 
 
I also state that I have/have not participated in any other research project in the past 3 
months. 
If I have, the details are as : 
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Patient’s consent:  
 
Participant Name: 
 
Date: 
 
Signature: 
 
 
 
Witness Name: 
 
Date: 
 
Signature: 
 
 
Investigators' confirming statement: 
 
 
I have given this research subject information on the study, which in my opinion is 
accurate and sufficient for the subject to understand fully the nature, risks and benefits 
of the study, and the rights of a research subject. There has been no coercion or undue 
influence. I have witnessed the signing of this document by the subject. 
 
Date:   
 
Investigator's Name: 
 
Investigator's signature: 
 
 
 
 
 
follows: 
Dr: on: (Phone and pager numbers) 
Date:  Witness: 
             (Please print name)  
Signature:                                               Signature:                                      
                  (of participant/volunteer)                       (of witness)       
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Withdrawal form Participation 
 
Protocol Title: A comparison of the effect of omeprazole and rabeprazole on 
clozapine serum concentration. 
 
An option should I wish to withdraw my consent to participate in the research 
protocol entitled above is to contact the researcher and/or return this slip. I understand 
that if I withdraw the research protocol my medical care, my relationship with the 
hospital and medical attendants will not be affected. 
 
Patient’s Name: 
Patient’s Signature: 
Date: 
 
Please detach the withdrawal of Participant Section and send to Dr. Glenys Dore 
(Figtree Ward, Macquarie Hospital) and if I would like to speak to a member of the 
study investigation team I may contact Dr. Glenys Dore (02-98881222). 
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